Document:

As of
October 31, 2012

 

NEVADA GOLD &
CASINOS, INC.

50 Briar Hollow Lane, Suite 500w

Houston, TX 77027

Attn: Jim Kohn, CFO

Fax No.: (713) 621-6919

 

NEVADA GOLD &
CASINOS, INC.

50 Briar Hollow Lane, Suite 500w

Houston, TX 77027

Attn: Branko Milosevic, Associate General Counsel

Fax No.: (713) 296-5070

 

		Re:	Amendment Number Four to Credit Agreement (this “Amendment”)

 

Ladies and Gentlemen:

 

Reference is made hereby
to that certain Credit Agreement, dated as of October 7, 2011 (as amended, restated, supplemented or otherwise modified from time
to time, the “Credit Agreement”), by and among Nevada Gold & Casinos, Inc., a Nevada corporation (“Parent”),
NG Washington, LLC, a Washington limited liability company (“NGWI”), NG Washington II, LLC, a Washington limited
liability company (“NGWII”), and NG Washington III, LLC, a Washington limited liability company (“NGWIII”
and together with NGWI and NGWII, are referred to hereinafter each individually as a “Borrower” and, individually
and collectively, jointly and severally, as the “Borrowers”), the lenders party to the Credit Agreement as “Lenders”
(each of such Lenders, together with their successors and permitted assigns, are referred to hereinafter as a “Lender”),
and Wells Fargo Gaming Capital, LLC, a Delaware limited liability company, in its capacity as administrative agent for the Lenders
and Bank Product Providers (in such capacity, together with its successors and assigns in such capacity, “Agent”).
Capitalized terms used and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement.

 

Subject to the terms
and conditions contained herein, Borrowers, Agent and Lenders have agreed to make certain amendments to the Credit Agreement.

 

Effective as of the
date hereof, Parent, Borrowers, Agent, and Lenders hereby agree to make the following amendments to the Credit Agreement:

 

1.Schedule 1.1
to the Credit Agreement is hereby amended by amending and restating the definitions of “Adjusted EBITDA”, “Corporate
Overhead”, “EBITDA”, “Fixed Charge Coverage Ratio”, “LIBOR Rate”, and “Senior Leverage
Ratio” as follows:

 

“Adjusted
EBITDA” means, with respect to any fiscal period, (a) EBITDA of Borrowers and NG South Dakota determined on a consolidated
basis for such fiscal period minus (b) Corporate Overhead for such fiscal period.

 

    	

    	 

    

“Corporate
Overhead” means the total corporate overhead expense of Parent, as recorded in accordance with GAAP excluding
(a) extraordinary, unusual, or non-recurring expenses or non-cash losses, (b) non-cash compensation expense (including deferred
non-cash compensation expense), or other non-cash expenses or charges, arising from the sale or issuance of Equity Interests, the
granting of stock options, and the granting of stock appreciation rights and similar arrangements (including any repricing, amendment,
modification, substitution, or change of any such Equity Interests, stock option, stock appreciation rights, or similar arrangements)
minus the amount of any such expenses or charges when paid in cash to the extent not deducted in the computation of net earnings
(or loss), and (c) non-cash losses on sales of fixed assets or write-downs of fixed or intangible assets of up to (i) $750,000
(in the aggregate for the foregoing clauses (a) through (c)) for the fiscal quarter ending January 31, 2013, and (ii) $500,000
(in the aggregate for the foregoing clauses (a) through (c)) for each fiscal quarter after the fiscal quarter ending January 31,
2013; provided, however, that, any transaction involving solely the Excluded Subsidiaries (and not any of the Loan
Parties) shall not be subject to the limitations described in the clauses (i) and (ii) above.

 

“EBITDA”
means, with respect to any fiscal period,

 

(a) Borrowers’
and NG South Dakota’s consolidated net earnings (or loss),

 

minus

 

(b)without duplication,
the sum of the following amounts of Borrowers and NG South Dakota (on a consolidated basis) for such period to the extent included
in determining consolidated net earnings (or loss) for such period:

 

(i)any extraordinary,
unusual, or non-recurring gains,

 

(ii)interest income,

 

plus

 

(c) without
duplication, the sum of the following amounts of Borrowers and NG South Dakota (on a consolidated basis) for such period to the
extent included in determining consolidated net earnings (or loss) for such period:

 

(i)any extraordinary,
unusual, or non-recurring expenses or non-cash losses,

 

(ii)interest expense,

 

(iii)tax expense based
on income, profits or capital, including federal, foreign, state, franchise and similar taxes (and for the avoidance of doubt,
specifically excluding any sales taxes or any other taxes held in trust for a Governmental Authority),

 

(iv)depreciation and
amortization for such period, in each case, determined on a consolidated basis in accordance with GAAP,

 

(v)non-cash compensation
expense (including deferred non-cash compensation expense), or other non-cash expenses or charges, arising from the sale or issuance
of Equity Interests, the granting of stock options, and the granting of stock appreciation rights and similar arrangements (including
any repricing, amendment, modification, substitution, or change of any such Equity Interests, stock option, stock appreciation
rights, or similar arrangements) minus the amount of any such expenses or charges when paid in cash to the extent not deducted
in the computation of net earnings (or loss),

 

    	2

    	 

    

(vi)costs, fees, charges,
or expenses incurred in connection with the transactions contemplated by the Agreement on or within one-hundred eighty (180) days
of the Closing Date; provided that the amounts necessary to pay all of such costs, fees, charges, or expenses are actually funded
on the Closing Date as reflected in the sources and uses delivered to Agent prior to the Closing Date that was accepted by Agent,

 

(vii)non-cash losses
on sales of fixed assets or write-downs of fixed or intangible assets, and

 

(viii)management fees
and expenses paid or accrued in accordance with Section 6.10(e) of the Agreement,

 

in each case, determined on a consolidated basis in
accordance with GAAP.

 

For the purposes
of calculating EBITDA for any fiscal period referred to in Section 7 of the Credit Agreement (a “Reference Period”),
if at any time during such Reference Period (and after the Closing Date), a Borrower or NG South Dakota shall have made a Permitted
Acquisition, EBITDA for such Reference Period shall be calculated after giving pro forma effect thereto (including pro
forma adjustments arising out of events which are directly attributable to such Permitted Acquisition, are factually supportable,
and are expected to have a continuing impact, in each case to be mutually and reasonably agreed upon by Borrowers and Agent) or
in such other manner acceptable to Agent as if any such Permitted Acquisition or adjustment occurred on the first day of such Reference
Period.

 

“Fixed
Charge Coverage Ratio” means, with respect to any fiscal period, the ratio of (a) TTM Adjusted EBITDA of Borrowers and
NG South Dakota (determined on a consolidated basis) for the twelve (12) month period most recently ended as of the end of such
fiscal period minus the sum of (i) Capital Expenditures of the Loan Parties made (to the extent not already incurred in a prior
period) or incurred during such fiscal period, (ii) all federal, state, and local income taxes of Parent paid in cash during such
fiscal period, and (iii) all Restricted Payments paid (whether in cash or other property, other than common Equity Interests) during
such fiscal period to (b) Fixed Charges for such fiscal period.

 

“LIBOR
Rate” means the greater of (a) 0.25 percent per annum, and (b) the rate per annum rate appearing on Macro*World’s
(https://capitalmarkets.mworld.com; the “Service”)
Page BBA LIBOR - USD (or on any successor or substitute page of such Service, or any successor to or substitute for such Service)
two (2) Business Days prior to the commencement of the requested Interest Period, for a term and in an amount comparable to the
Interest Period and the amount of the LIBOR Rate Loan requested (whether as an initial LIBOR Rate Loan or as a continuation of
a LIBOR Rate Loan or as a conversion of a Base Rate Loan to a LIBOR Rate Loan) by Borrowers in accordance with the Agreement, which
determination shall be conclusive in the absence of manifest error.

 

“Senior
Leverage Ratio” means, as of any date of determination, the ratio of (a) the sum of the outstanding amount of the Term
Loan as of such date plus the outstanding amount of any Indebtedness of NG South Dakota as of such date, to (b) TTM Adjusted EBITDA
of Borrowers and NG South Dakota (determined on a consolidated basis) for the twelve (12) month period most recently ended as of
such date.

 

    	3

    	 

    

2.Section 7.2
of the Credit Agreement is hereby amended by replacing the reference to “1.25” with “1.15”.

 

3.Section 7.5
of the Credit Agreement and Schedule 7.5 to the Credit Agreement are hereby deleted in their entirety.

 

4.Exhibit C-1
to the Credit Agreement is hereby amended by deleting item 5 from Schedule 4 thereof.

 

Each Borrower hereby
acknowledges and agrees that as of October 31, 2012, the outstanding principal amount of the Term Loan is $10,000,000. For the
avoidance of doubt, the foregoing does not include any interest that is accrued and unpaid. Effective on the date hereof, each
Loan Party, for itself and on behalf of its successors, assigns, and officers, directors, employees, agents and attorneys, and
any Person acting for or on behalf of, or claiming through it, hereby waives, releases, remises and forever discharges Agent and
Lender, each of their respective Affiliates, and each of their respective successors in title, past, present and future officers,
directors, employees, limited partners, general partners, investors, attorneys, assigns, subsidiaries, shareholders, trustees,
agents and other professionals and all other persons and entities to whom any Agent or Lender would be liable if such persons or
entities were found to be liable to such Loan Party (each a “Releasee” and collectively, the “Releasees”),
from any and all claims, suits, liens, lawsuits, adverse consequences, amounts paid in settlement, debts, deficiencies, diminution
in value, disbursements, demands, obligations, liabilities, causes of action, damages, losses, costs and expenses of any kind or
character, whether based in equity, law, contract, tort, implied or express warranty, strict liability, criminal or civil statute
or common law (each a “Claim” and collectively, the “Claims”), whether known or unknown,
fixed or contingent, direct, indirect, or derivative, asserted or unasserted, matured or unmatured, foreseen or unforseen, past
or present, liquidated or unliquidated, suspected or unsuspected, which such Loan Party ever had from the beginning of the world
to the date hereof, now has, or might hereafter claim to have had against any such Releasee which relates, directly or indirectly
to the Credit Agreement, any other Loan Document, or to any acts or omissions of any such Releasee with respect to the Credit Agreement
or any other Loan Document, or to the lender-borrower relationship evidenced by the Loan Documents. As to each and every claim
released hereunder, each of each Loan Party hereby represents that it has received the advice of legal counsel with regard to the
releases contained herein, and having been so advised, specifically waives the benefit of the provisions of Section 1542 of the
Civil Code of California which provides as follows:

 

“A GENERAL RELEASE
DOES NOT EXTEND TO CLAIMS WHICH A CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE,
WHICH IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.”

 

As to each and every
claim released hereunder, each Loan Party also waives the benefit of each other similar provision of applicable federal or state
law, if any, pertaining to general releases after having been advised by its legal counsel with respect thereto.

 

Each Loan Party acknowledges
that it may hereafter discover facts different from or in addition to those now known or believed to be true with respect to such
claims, demands, or causes of action and agrees that this instrument shall be and remain effective in all respects notwithstanding
any such differences or additional facts. Each Loan Party understands, acknowledges and agrees that the release set forth above
may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding
which may be instituted, prosecuted or attempted in breach of the provisions of such release.

 

    	4

    	 

    

Each Loan Party, for
itself and on behalf of its successors, assigns, and officers, directors, employees, agents and attorneys, and any Person acting
for or on behalf of, or claiming through it, hereby absolutely, unconditionally and irrevocably, covenants and agrees with and
in favor of each Releasee above that it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Releasee
on the basis of any claim released, remised and discharged by such Person pursuant to the above release. Each of Loan Party further
agrees that it shall not dispute the validity or enforceability of the Credit Agreement or any of the other Loan Documents or any
of its obligations thereunder, or the validity, priority, enforceability or the extent of Agent’s Lien on any item of Collateral
under the Credit Agreement or the other Loan Documents. If any Loan Party or any of its successors, assigns, or officers, directors,
employees, agents or attorneys, or any Person acting for or on behalf of, or claiming through them violate the foregoing covenant,
such Person, for itself and its successors, assigns and legal representatives, agrees to pay, in addition to such other damages
as any Releasee may sustain as a result of such violation, all attorneys’ fees and costs incurred by such Releasee as a result
of such violation.

 

Each Borrower hereby
reconfirms its obligations pursuant to Section 2.5 of the Credit Agreement to pay and reimburse Agent for all costs and
expenses (including, without limitation, reasonable documented fees of counsel) incurred in connection with the negotiation, preparation,
execution and delivery of this Amendment and all other documents and instruments delivered in connection herewith, in each case
subject to the terms and conditions of the Credit Agreement.

 

The Credit Agreement,
as amended hereby, and each of the other Loan Documents, as amended as of the date hereof, shall be and remain in full force and
effect in accordance with their respective terms and hereby are restated, ratified and confirmed in all respects. The execution,
delivery, and performance of this Amendment shall not operate, except as expressly set forth herein, as a waiver of, consent to,
or a modification or amendment of, any right, power, or remedy of Agent or any Lender under the Credit Agreement or any other Loan
Document. Except for the amendments to the Credit Agreement expressly set forth herein, the Credit Agreement and the other Loan
Documents shall remain unchanged and in full force and effect. The amendments and modifications set forth herein are limited to
those specified herein, shall not apply with respect to any facts or occurrences other than those on which the same are based,
shall neither excuse future non-compliance with the Loan Documents nor operate as a waiver of any Default or Event of Default,
shall not operate as a consent to any further or other matter under the Loan Documents and shall not be construed as an indication
that any future amendment or modification of covenants or any other provision of the Credit Agreement will be agreed to, it being
understood that the granting or denying of any amendment or modification which may hereafter be requested by Borrower remains in
the sole and absolute discretion of Agent and Lenders in accordance with Section 14.1 of the Credit Agreement.

 

Each Loan Party hereby
represents and warrants that (a) the execution, delivery, and performance of this Amendment are within its limited liability company,
corporate or similar powers, have been duly authorized by all necessary limited liability, corporate or other action of such Loan
Party, and are not in contravention of any material provision of federal, state, or local law or regulation applicable to it, or
any order, judgment or decree of any court or other Governmental Authority binding on it, or of the terms of its charter or bylaws,
or of any material contract of such Loan Party (except as would not reasonably be expected to have a Material Adverse Effect),
(b) after giving effect to this Amendment, as of the date hereof, no Default or Event of Default shall have occurred and be continuing,
and (c) after giving effect to this Amendment, the representations and warranties in the Credit Agreement and the other Loan Documents
shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations
and warranties that already are qualified or modified by materiality in the text thereof) on and as of the date hereof, as though
made on such date (except to the extent that such representations and warranties relate solely to an earlier date).

 

    	5

    	 

    

Each Loan party hereby
(a) acknowledges and reaffirms its obligations owing to Agent and Lenders under each Loan Document to which it is a party, and
(b) agrees that each of the Loan Documents to which it is a party is and shall remain in full force and effect as modified hereby.
Each Loan Party hereby further ratifies and reaffirms the validity and enforceability of all of the liens and security interests
heretofore granted, pursuant to and in connection with the Guaranty and Security Agreement or any other Loan Document, to Agent,
as collateral security for the obligations under the Loan Documents in accordance with their respective terms, and acknowledges
that all of such Liens and security interests, and all Collateral heretofore pledged as security for such obligations, continue
to be and remain collateral for such obligations from and after the date hereof. All obligations owing by each Loan Party to Agent
and Lenders are unconditionally owing by such Loan Party to Agent and Lenders, without offset, defense, withholding, counterclaim
or deduction of any kind, nature or description whatsoever.

 

THIS AMENDMENT SHALL
BE SUBJECT TO THE PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN SECTION
12 OF THE CREDIT AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS.

 

This Amendment may
be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered,
shall be deemed to be an original, and all of which, taken together, shall constitute but one and the same Amendment. Delivery
of an executed counterpart of this Amendment by telefacsimile or other electronic image scan transmission (e.g., “PDF”
or “tif” via email) shall be equally effective as delivery of an original executed counterpart of this Amendment. Any
party delivering an executed counterpart of this Amendment by telefacsimile or other electronic image scan transmission also shall
deliver an original executed counterpart of this Amendment but the failure to deliver an original executed counterpart shall not
affect the validity, enforceability, and binding effect of this Amendment.

 

Each of the
undersigned Guarantors consent to the amendments to the Credit Agreement contained herein. Although the undersigned Guarantors
have been informed of the matters set forth herein and have consented to same, each Guarantor understands that the Lender Group
has no obligations to inform it of such matters in the future or to seek its acknowledgement or agreement to future consents or
amendments, and nothing herein shall create such a duty.

 

This Amendment is a
Loan Document.

 

 

[Signature pages to follow.]

 

    	6

    	 

    
 

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to be duly executed and delivered by their respective officers thereunto duly authorized
as of the date first written above.

 

 

	 	Very
Truly Yours,
	 	 
	 	
        WELLS FARGO GAMING
        CAPITAL, LLC,

        a Delaware limited liability company, as Agent and a Lender

	 	 
	 	 
	 	By:	/s/ Suzanne Fuller
	 	Name:	Suzanne Fuller
	 	Title:	Managing Director
	 	 

 

 

Accepted, acknowledged, and agreed:

 

	
        NEVADA GOLD & CASINOS, INC.,

        a Nevada corporation

	 
	 
	By:	/s/ Ernest E. East
	Name:	Ernest E. East
	Title:	President
	 
	NG WASHINGTON, LLC,

a Washington limited liability company
	 
	 
	By:	/s/ Ernest E. East
	Name:	Ernest E. East
	Title:	Manager
	 
	NG WASHINGTON II, LLC,

a Washington limited liability company
	 
	 
	By:	/s/ Ernest E. East
	Name:	Ernest E. East
	Title:	Manager
	 	 
	 

    	7

    	 

    

 

	NG WASHINGTON III, LLC,

a Washington limited liability company
	 
	 
	By:	/s/ Ernest E. East
	Name:	Ernest E. East
	Title:	Manager

 

  

	NG WASHINGTON II HOLDINGS, LLC,

    a Delaware limited liability company
	 
	 
	By:	/s/ Ernest E. East
	Name:	Ernest E. East
	Title:	Manager
	 
	NG SOUTH DAKOTA, LLC,

a South Dakota limited liability company
	 
	 
	By:	/s/ Ernest E. East
	Name:	Ernest E. East
	Title:	Manager
	 
	NEVADA GOLD SPEEDWAY, LLC,
    

    a Nevada  limited liability company
	 
	 
	By:	/s/ Ernest E. East
	Name:	Ernest E. East
	Title:	Manager
	 	 
	 
	A.G. TRUCANO, SON & GRANDSONS, INC.,
    

    a South Dakota corporation
	 
	 
	By:	/s/ Ernest E. East
	Name:	Ernest E. East
	Title:	President

 

    	8EXHIBIT 10.1

 

 

    	 

    	Page 2 of 32

    

 

Section B - Supplies or Services and Prices

 

	ITEM NO	 	SUPPLIES/SERVICES	 	QUANTITY	 	 	UNIT	 	 	UNIT PRICE	 	 	AMOUNT	 
	0001	 	 	 	 	*		 	 	*		 	$	*		 	$	827,800.92	 
	 	 	Vector Seed Stock	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FFP	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FOB: Destination	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	MILSTRIP: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	PURCHASE REQUEST NUMBER: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	NET AMT	 	 	$	827,800.92	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	ACRN AA	 	 	 	 	 	 	 	 	 	 	 	 	 	$	827,800.92	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CIN: N3239812RCAP0090001

 

	ITEM NO	 	SUPPLIES/SERVICES	 	QUANTITY	 	 	UNIT	 	 	UNIT PRICE	 	 	AMOUNT	 
	0002	 	 	 	 	*		 	 	*		 	$	*		 	$	2,600,005.92	 
	 	 	Malaria Manufacture of 3 AD Vectors	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FFP	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FOB: Destination	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	MILSTRIP: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	PURCHASE REQUEST NUMBER: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	NET AMT	 	 	$	2,600,005.92	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	ACRN AA	 	 	 	 	 	 	 	 	 	 	 	 	 	$	2,600,005.92	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CIN: N3239812RCAP0090002

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 3 of 32

    

 

	ITEM NO	 	SUPPLIES/SERVICES	 	QUANTITY	 	 	UNIT	 	 	UNIT PRICE	 	 	AMOUNT	 
	0003	 	 	 	 	*		 	 	*		 	$	*		 	$	92,192.76	 
	 	 	Stability Study	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FFP	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Stability Study	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FOB: Destination	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	MILSTRIP: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	PURCHASE REQUEST NUMBER:N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	NET AMT	 	 	$	92,192.76	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	ACRN AA	 	 	 	 	 	 	 	 	 	 	 	 	 	$	92,192.76	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CIN: N3239812RCAP0090003

 

	ITEM NO	 	SUPPLIES/SERVICES	 	QUANTITY	 	 	UNIT	 	 	UNIT PRICE	 	 	AMOUNT	 
	1001	 	 	 	 	*		 	 	*		 	$	*		 	$	140,192.88	 
	OPTION	 	Stability Study- Option 1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FFP	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Stability Study	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FOB: Destination	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	MILSTRIP: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	PURCHASE REQUEST NUMBER: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	NET AMT	 	 	$	140,192.88	 

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 4 of 32

    

 

	ITEM NO	 	SUPPLIES/SERVICES	 	QUANTITY	 	 	UNIT	 	 	UNIT PRICE	 	 	AMOUNT	 
	2001	 	 	 	 	*		 	 	*		 	$	*		 	$	74,999.88	 
	OPTION	 	Clinical Trial Insurance- Option 2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FFP	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	FOB: Destination	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	MILSTRIP: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	PURCHASE REQUEST NUMBER: N3239812RCAP009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	NET AMT	 	 	$	74,999.88	 

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 5 of 32

    
 

Section C - Descriptions and Specifications

 

STATEMENT OF WORK

Please see Attachment 1, Statement of Work and Attachment 2,
Statement of Work Appendix H,: Manufacture of Three Adenovirus Vectors Encoding Plasmodium falciparum Sporozoite/Liver Stage
Antigens with Stability Program.

Contractor agrees to use its best efforts to achieve the objectives
specified in the Technical Proposal and all obligations under this contract.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 6 of 32

    

 

Section E - Inspection and Acceptance

 

ADMINISTRATION CONTACTS

Contract Specialist: Mr. Thomas Hood

Phone Number: 301 619 9236

Email: thomas.hood@med.navy.mil

 

Contracting Officer’s Representative: *

Phone Number: *

Email: *

 

INSPECTION AND ACCEPTANCE TERMS

 

Supplies/services will be inspected/accepted at:

 

	CLIN	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	0001	Destination	Government	Destination	Government
	0002	Destination	Government	Destination	Government
	0003	Destination	Government	Destination	Government
	1001	Destination	Government	Destination	Government
	2001	Destination	Government	Destination	Government

 

CLAUSES INCORPORATED BY REFERENCE

 

	52.246-2	Inspection Of Supplies—Fixed Price	AUG 1996   
	52.246-7	Inspection Of Research And Development Fixed Price	AUG 1996   
	52.246-16	Responsibility For Supplies	APR 1984   

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 7 of 32

    

 

Section F - Deliveries or Performance

 

DELIVERY INFORMATION

 

	CLIN	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	UIC
	 	 	 	 	 
	0001	
        POP * TO

        *
	N/A	
        NAVAL MEDICAL RESEARCH CENTER (NMRC)

        503 ROBERT GRANT AVENUE

        SILVER SPRING MD 20910

        FOB: Destination
	N32398
	 	 	 	 	 
	0002	
        POP * TO

        *
	N/A	
        (SAME AS PREVIOUS LOCATION)

        FOB: Destination
	N32398
	 	 	 	 	 
	0003	
        POP 29-SEP-2012 TO

        28-SEP-2015
	N/A	
        (SAME AS PREVIOUS LOCATION)

        FOB: Destination
	N32398
	 	 	 	 	 
	1001	
        POP 29-SEP-2015 TO

        28-SEP-2017
	N/A	
        (SAME AS PREVIOUS LOCATION)

        FOB: Destination
	N32398
	 	 	 	 	 
	2001	
        POP * TO

        *
	N/A	
        (SAME AS PREVIOUS LOCATION)

        FOB: Destination
	N32398

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 8 of 32

    

 

Section G - Contract Administration Data

 

ACCOUNTING AND APPROPRIATION DATA

 

	AA: 1721319 B521 255 32398 0 068688 2D CAP009
	COST CODE: 323982AB508Q
	AMOUNT: $3,519,999.60
	CIN N3239812RCAP0090001: $827,800.92
	CIN N3239812RCAP0090002: $2,600,005.92
	CIN N3239812RCAP0090003: $92,192.76

 

CLAUSES INCORPORATED BY FULL TEXT

 

252.232-7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS
(JUN 2012)

 

(a) Definitions. As used in this clause—

 

“Department of Defense Activity Address Code (DoDAAC)”
is a six position code that uniquely identifies a unit, activity, or organization.

 

“Document type” means the type of payment request
or receiving report available for creation in Wide Area WorkFlow (WAWF).

 

“Local processing office (LPO)” is the office responsible
for payment certification when payment certification is done external to the entitlement system.

 

(b) Electronic invoicing. The WAWF system is the method to electronically
process vendor payment requests and receiving reports, as authorized by DFARS 252.232-7003, Electronic Submission of Payment Requests
and Receiving Reports.

 

(c) WAWF access. To access WAWF, the Contractor shall—

 

(1) Have a designated electronic business point of
contact in the Central Contractor Registration at https://www.acquisition.gov; and

 

(2) Be registered to use WAWF at https://wawf.eb.mil/
following the step-by-step procedures for self-registration available at this Web site.

 

(d) WAWF training. The Contractor should follow the training
instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through
WAWF. Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.mil/.

 

(e) WAWF methods of document submission. Document submissions
may be via Web entry, Electronic Data Interchange, or File Transfer Protocol.

 

(f) WAWF payment instructions. The Contractor must use the following
information when submitting payment requests and receiving reports in WAWF for this contract/order:

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 9 of 32

    

 

(1) Document type. The Contractor shall use the following document type(s).

 

2 IN 1 SERVICES ONLY 

 

 

(2) Inspection/acceptance location. The Contractor
shall select the following inspection/acceptance location(s) in WAWF, as specified by the contracting officer.

 

DESTINATION / DESTINATION 

 

 

(3) Document routing. The Contractor shall use the
information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving
reports in the

system.

 

 Routing Data Table*

	Field Name in WAWF	 	Data to be entered in WAWF
	Pay Official DoDAAC	 	HQ0248
	Issue By DoDAAC	 	N62645
	Admin DoDAAC	 	N62645
	Inspect By DoDAAC	 	N/A
	Ship To Code	 	N/A
	Ship From Code	 	N/A
	Mark For Code	 	N/A
	Service Approver (DoDAAC)	 	N/A
	Service Acceptor (DoDAAC)	 	N32398
	Accept at Other DoDAAC	 	N/A
	LPO DoDAAC	 	N32398
	DCAA Auditor DoDAAC	 	N/A
	Other DoDAAC(s)	 	N/A

 

(4) Payment request and supporting documentation.
The Contractor shall ensure a payment request includes appropriate contract line item and subline item descriptions of the work
performed or supplies delivered, unit price/cost per unit, fee (if applicable), and all relevant back-up documentation, as defined
in DFARS Appendix F, (e.g. timesheets) in support of each payment request.

 

(5) WAWF email notifications. The Contractor shall
enter the email address identified below in the “Send Additional Email Notifications” field of WAWF once a document
is submitted in the system.

 

* 

 

 

(g) WAWF point of contact.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 10 of 32

    

 

(1) The Contractor may obtain clarification regarding
invoicing in WAWF from the following contracting activity's WAWF point of contact.

 

* 

 

 

(2) For technical WAWF help, contact the WAWF helpdesk
at 866-618-5988.

 

(End of clause)

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 11 of 32

    

 

Section H - Special Contract Requirements

 

SPECIAL CONTRACT REQUIREMENTS

H.1 INVENTION DISCLOSURES AND REPORTS

 

(a) In accordance with the requirements of the Patent Rights
clause of this contract, the contractor shall submit “Report of Inventions and Subcontracts” (DD Form 882) along with
written disclosure of inventions to the designated Contract Administrator.

 

(b) The Contract Administrator will forward such reports and
disclosures directly to the appropriate Patent Counsel, designated below, for review and recommendations, after which the reports
will be returned to the Contract Administrator.

 

Name and address of Patent Counsel:

 

Office of Legal and Technology Services

Naval Medical Research Center (Code 1URO)

503 Robert Grant Avenue, Suite 1W/15

Silver Spring, MD 20910

 

Phone: 301-319-7503/7429

 

(c) The above designated Patent Counsel will represent the Procurement
Contracting Officer with regard to invention reporting matters arising under this contract.

 

(d) A copy of each report and disclosure shall be forwarded
to the Procuring Contracting Officer.

 

(e) The contractor shall furnish the Contracting Officer a final
report within three (3) months after completion of the contracted work listing all subject inventions or certifying that there
were no such inventions, and listing all subcontracts at any tier containing a patent rights clause or certifying that there were
no such subcontracts.

 

H.2 NOTICE REGARDING THE DISSEMINATION OF EXPORT-CONTROLLED
TECHNICAL DATA

 

(a) Export of information contained herein, which includes release
to foreign nationals within the United States, without first obtaining approval or license from the Department of State for items
controlled by the International Traffic in Arms Regulations (ITARS), or the Department of Commerce for items controlled by the
Export Administration Regulations (EAR), may constitute a violation of law.

 

(b) For violation of export laws, the contractor, its employees,
officials or agents are subject to:

 

		(1)	Imprisonment and/or imposition of criminal fines; and

		(2)	Suspension or debarment from future Government contracting
actions.

 

(c) The Government shall not be liable for any unauthorized
use or release of export-controlled information, technical data or specifications in this contract.

 

(d) The contractor shall include the provisions or paragraphs
(a) through (c) above in any subcontracts awarded under this contract.

 

H.3 PERFORMANCE BY FOREIGN NATIONALS
OR FOREIGN OWNERSHIP, CONTROL OR INFLUENCE (FOCI) ORGANIZATIONS

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 12 of 32

    

 

In accordance with 8 U.S.C.1324a, it is unlawful to hire for
employment in the U.S. an individual without verifying that individual’s employment authorization. 8 CFR 274a.2 VERIFICATION
OF EMPLOYMENT ELIGIBILITY identifies the official documents that establish employment eligibility.

 

Prior to performance of work by a foreign national as a result
of this contract, the employer shall provide the Contracting Officer the name of the foreign national and identify the type of
form(s) produced for verification of employment status.

 

Should the foreign national’s performance require access
to DoD facilities, the employer shall coordinate with the sponsor providing access, in order to submit the following:

 

		1.	Individual’s Name

		2.	Date/place of birth

		3.	Citizenship

		4.	Date and Location of the Visit

		5.	Purpose of the Visit

		6.	Passport Number

		7.	Employer’s Verification of Work Authorization

 

This information shall be forwarded to the Contracting Officer
at least thirty days prior to the visit taking place. Failure to provide this information within this time frame may prevent the
individual(s) from entry into the DoD facilities.

 

The offeror shall disclose if the company (or individual) is
a FOCI. A FOCI organization includes sole proprietorships, partnerships, and corporations, and the divisions and subsidiaries of
the corporation where: (a) 51% or more of the controlling (voting) stock is foreign-owned; or (b) parent organization is incorporated
or otherwise charted in a country foreign to the U.S.; and (c) the organization is not performing a state function (any organization
performing a state function falls under IPO authority). A division or subsidiary of an organization having a location in the U.S.
is still considered FOCI if the parent corporation is a FOCI. A university, college, or not-for-profit organization that is chartered,
incorporated, or otherwise called into being in a country foreign to the U.S. and not performing a state function is FOCI. A FOCI
person is a non-U.S. citizen. Resident aliens are considered FOCI for licensing and technology transfer purposes. Approval by the
U.S. Trade Representative may be required prior to executing a contract with a FOCI.

 

H.4 ENVIRONMENTAL STANDARDS

 

By accepting funds under this contract, the contractor assures
that it will:

 

Comply with applicable provisions of the Clean Air Act (42 U.S.C.
7401, et seq.) and Clean Water Act (33 U.S.C. 1251, et.seq.), as implemented by Executive Order 11738 [3 CFR, 1971-1975 comp.,
p. 799] and Environmental Protection Agency (EPA) rules at 40 CFR Part 15. In accordance with the EPA rules, the recipient further
agrees that it will:

 

Not use any facility on the EPA’s List of Violating Facilities
in performing any award that is nonexempt under 40 CFR 15.5 (awards of less than $100,000, and certain other awards, exempt from
the EPA regulations), as long as the facility remains on the list.

 

Notify the awarding agency if it intends to use a facility in
performing this award that is on the List of Violating Facilities or that the Recipient knows has been recommended to be placed
on the List of Violating Facilities.

 

Identify to the awarding agency any impact this award may have
on:

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 13 of 32

    

 

The quality of the human environment, and provide help the agency
may need to comply with the National Environmental Policy Act (NEPA, at 42 U.S.C. 4321, et seq.) and to prepare Environmental Impact
Statements or other required environmental documentation. In such cases, the Recipient agrees to take no action that will have
an adverse environmental impact (e.g., physical disturbance of a site such as breaking of ground) until the agency provides written
notification of compliance with the environmental impact analysis process.

 

Coastal barriers, and provide help the agency may need to comply
with the Coastal Barriers Resource Act (16 U.S.C. 3501, et seq.), concerning preservation of barrier resources.

 

Any existing or proposed component of the National Wild and
Scenic Rivers system, and provide help the agency may need to comply with the Wild and Scenic Rivers Act of 1968 (16 U.S.C. 1271,
et seq.).

 

H. 5 AUTHORIZED CHANGES ONLY
BY THE CONTRACTING OFFICER

 

(a) Except as specified in paragraph (b) below, no order, statement,
or conduct of Government personnel who visit the contractor’s facilities or in any other manner communicates with contractor
personnel during the performance of this contract shall constitute a change under the “Changes” clause of this contract.

 

(b) The contractor shall not comply with any order, direction
or request of Government personnel unless it is issued in writing and signed by the Contracting Officer, or is pursuant to specific
authority otherwise included as a part of this contract.

 

(c) The Contracting Officer is the only person authorized to
approve changes in any of the requirements of this contract and notwithstanding provisions contained elsewhere in this contract,
the said authority remains solely the Contracting Officer’s. In the event the contractor effects any change at the direction
of any person other than the Contracting Officer, the change will be considered to have been made without authority and no adjustment
will be made in the contract price to cover any increase in charges incurred as a result thereof.

 

H.6 REVIEW OF PRESS RELEASES

 

The contractor agrees to accurately and factually represent
the work conducted under the contract in all press releases. Misrepresenting contract results or releasing information that is
injurious to the integrity of the Government may be construed as improper conduct. Press releases shall be considered to include
the public release of information to any medium, excluding peer-reviewed scientific publications. The contractor shall ensure that
the Contracting Officer has received an advance copy of any press release related to the contract for review and comments at least
five (5) working days prior to proposed issuance. After receipt of the Government’s comments, the contractor shall provide
a copy to the Contracting Officer prior to issuance of the press release.

 

H.7 CONTRACTOR'S PROPOSAL

 

Performance of this contract by the contractor shall be conducted
and performed in accordance with detailed obligations to which the contractor committed itself in Proposal dated 26 September 2012
in response to NAVMEDLOGCOM Sole Sourec RFP Letter sent 20 August 2012..

 

H.8 RESEARCH CONDUCT

 

Research provided under this contract must be conducted in accordance
with all state, federal, Department of Defense, Department of the Navy, and command laws, regulations, policies, and procedures
that govern the conduct of regulated research. Federal regulations governing current Good Clinical Practice (cGCP) are found in
21CFR 11, 50, 54, 56, 312, and 314 and important guidelines are in the FDA Information Sheets. Additional regulations for human
subjects protection are found in 45CFR 46. The International Convention on Harmonization Guidelines for Good Clinical Practice
are also standards governing the conduct of research trials. Reference for military regulations and policy governing regulated
research may be found at http://www.med.navy.mil/bumed/humanresearch/resource/Pages/ReferenceMaterial.aspx.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 14 of 32

    

 

This is a non personal services contract for research and development.
The Federal Tort Claims Act does not apply.

 

H.9 REIMBURSEMENT OF TRAVEL, PER DIEM, AND SPECIAL MATERIAL
COSTS

 

(a)    Area of Travel. Performance under this contract may require
travel by contractor personnel. If travel, domestic or overseas, is required, the contractor is responsible for making all necessary
arrangements for its personnel. These include but are not limited to: medical examinations, immunizations, passports/visas/etc.,
and security clearances.

 

(b)    Travel Policy. The Government will reimburse the contractor
for allowable travel costs incurred by the contractor in performance of the contract in accordance with FAR 31.205-46. Travel required
for tasks assigned under this contract shall be governed in accordance with: Federal Travel Regulations, prescribed by the General
Services Administration for travel in the conterminous 48 United States, (hereinafter the FTR); Joint Travel Regulation, Volume
2, DoD Civilian Personnel, Appendix A, prescribed by the Department of Defense, for travel in Alaska, Hawaii, The Commonwealth
of Puerto Rico, and territories and possessions of the United States (hereinafter JTR); and Standardized Regulations (Government
Civilians, Foreign Areas), Section 925, "Maximum Travel Per Diem Allowances for Foreign Areas," prescribed by the Department
of State, for travel in areas not covered in the FTR or JTR (hereinafter the SR).

 

(c)    Travel. Travel and subsistence are authorized for travel
beyond a fifty-mile radius of the contractor’s office whenever a task assignment requires work to be accomplished at a temporary
alternate worksite. No travel or subsistence shall be charged for work performed within a fifty-mile radius of the contractor’s
office. The contractor shall not be paid for travel or subsistence for contractor personnel who reside in the metropolitan area
in which the tasks are being performed. Travel performed for personal convenience, in conjunction with personal recreation, or
daily travel to and from work at the contractor’s facility will not be reimbursed.

 

   (1) For travel costs other than described
in paragraph (c) above, the contractor shall be paid on the basis of actual amount paid to the extent that such travel is necessary
for the performance of services under the contract and is authorized by the COR in writing.

 

   (2) When transportation by privately owned
conveyance is authorized, the contractor shall be paid on a mileage basis not to exceed the applicable Government transportation
rate as contained in the FTR, JTR or SR. Authorization for the use of privately owned conveyance shall be indicated in the basic
contract. Distances traveled between points shall be shown on invoices as listed in standard highway mileage guides. Reimbursement
will not exceed the mileage shown in the standard highway mileage guides.

 

   (3) The contractor agrees, in the performance
of necessary travel, to use the lowest cost mode commensurate with the requirements of the mission as set forth in the basic contract
and in accordance with good traffic management principles. When it is necessary to use air or rail travel, the contractor agrees
to use coach, tourist class, or similar accommodations to the extent consistent with the successful and economical accomplishment
of the mission for which the travel is being performed.

 

   (4) The contractor’s invoices shall
include receipts or other evidence substantiating actual costs incurred for authorized travel. In no event will such payments exceed
the rates of common carriers.

 

(d)    Vehicle and/or Truck Rentals. The contractor shall be reimbursed
for actual rental/lease of special vehicles and/or trucks (i.e., of a type not normally used by the contractor in the conduct of
its business) only if authorized in the basic contract or upon approval by the COR. Reimbursement of such rental shall be made
based on actual amounts paid by the contractor. Use of rental/lease costs of vehicles and/or trucks that are of a type normally
used by the contractor in the conduct of its business are not subject to reimbursement.

 

(e)   Car Rental. The contractor shall be reimbursed for car rental,
exclusive of mileage charges, as authorized in the basic contract or upon approval by the COR, when the services are required to
be performed beyond the normal commuting distance from the contractor’s facilities. Car rental for a team on Temporary Duty
(TDY) at one site will be allowed for a minimum of four (4) persons per car, provided that such number or greater comprise the
TDY team.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 15 of 32

    

 

(f)    Per Diem. The contractor shall not be paid for per diem
for contractor personnel who reside in the metropolitan areas in which the tasks are being performed. Per Diem shall not be paid
on services performed within a fifty-mile radius of the contractor’s home office or the contractor’s local office.
Per Diem is authorized for contractor personnel beyond a fifty-mile radius of the contractor’s home or local offices whenever
a task assigned requires work to be done at a temporary alternate worksite. Per Diem shall be paid to the contractor only to the
extent that overnight stay is necessary and authorized under this contract. The authorized per diem rate shall be the same as the
prevailing per diem in the worksite locality. These rates will be based on rates contained in the FTR, JTR or SR. The applicable
rate is authorized at a flat seventy-five (75%) percent on the day of departure from contractor’s home or local office, and
on the day of return. Reimbursement to the contractor for per diem shall be limited to actual payments to per diem defined herein.
The contractor shall provide actual payments of per diem defined herein. The contractor shall provide supporting documentation
(e.g., signed travel expense reports) for per diem expenses as evidence of actual payment.

 

(g)    Shipboard Stays. Whenever work assignments require temporary
duty aboard a Government ship, the contractor will be reimbursed at the per diem rates identified in paragraph C8101.2C or C81181.3B(6)
of the Department of Defense Joint Travel Regulations, Volume II.

 

(h)    Special Material. “Special material” includes
only the costs of material, supplies, or services which is peculiar to the ordered services and which is not suitable for use in
the course of the contractor’s normal business. It shall be furnished pursuant to specific authorization approved by the
COR. The contractor will be required to support all material costs claimed by its costs less any applicable discounts. “Special
materials” include, but are not limited to, graphic reproduction expenses, or technical illustrative or design requirements
needing special processing.

 

The Contractor shall ensure that the requested travel costs
will not exceed what the Government has pre-authorized. Contractor personnel must follow established Government travel requirements,
complete all forms, and obtain the required signatures prior to any travel. The Contractor may be required to coordinate with other
DOD and industry for travel. Trip reports will be required at the direction of the Government.

 

The Contractor may be required to attend various meetings and
reviews or to participate in Government projects. Travel may be CONUS as well as OCONUS. Reimbursements for travel will be in accordance
with JTR and will in no case exceed those travel costs allowed by the JTR unless approved by the Government. No surcharges shall
be authorized for travel costs other than the Contractor’s G&A rate approved by the Defense Contract Audit Agency (DCAA).
No fee or profit shall be applied to travel costs.

 

Any OCONUS/FOREIGN travel by contractor personnel shall be
in accordance with procedures for entering into the Area of Responsibility (e.g., CENTCOM). Refer to the Foreign Clearance Guide
at https://www.fcg.pentagon.mil.

 

H.10 STANDARD FORMAT REQUIREMENTS FOR SCIENTIFIC AND TECHNICAL
REPORTS

 

The contractor shall comply with the requirements of SECNAVINST
3900.29E “Standard Format Requirements for Scientific and Technical Reports” in preparing scientific and technical
reports delivered under the contract.

 

H.11 INDIRECT COST LIMITATION FOR BASIC RESEARCH AWARDS

 

Indirect costs may be restricted to less than 35% of the total
award value. The 2008 DoD Appropriations Act (Public Law 110-116, Section 8115), 2009 DoD Appropriations Act (Public Law 110-329,
Section 8109), and the 2010 DoD Appropriations Act (Public Law 111-118, Section 8101) applied this restriction to awards made using
fiscal year 2008, 2009, and 2010 Basic Research funds (DoD Budget Activity 6.1). This restriction does not apply to awards made
using fiscal year 2011 Basic Research funds but may apply to future awards.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 16 of 32

    

 

 

Section I - Contract Clauses

 

CLAUSES INCORPORATED BY REFERENCE

  

	52.202-1	Definitions	JAN 2012   
	52.203-3	Gratuities	APR 1984   
	52.203-5	Covenant Against Contingent Fees	APR 1984   
	52.203-7	Anti-Kickback Procedures	OCT 2010   
	52.203-8	Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity	JAN 1997   
	52.203-10	Price Or Fee Adjustment For Illegal Or Improper Activity	JAN 1997   
	52.203-11	Certification And Disclosure Regarding Payments To Influence Certain Federal Transactions	SEP 2007   
	52.203-12	Limitation On Payments To Influence Certain Federal Transactions	OCT 2010   
	52.204-4	Printed or Copied Double-Sided on Postconsumer Fiber Content Paper	MAY 2011   
	52.204-7	Central Contractor Registration	FEB 2012   
	52.204-10	Reporting Executive Compensation and First-Tier Subcontract Awards	FEB 2012   
	52.209-6	Protecting the Government's Interest When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment	DEC 2010   
	52.215-2	Audit and Records—Negotiation	OCT 2010   
	52.215-8	Order of Precedence—Uniform Contract Format	OCT 1997   
	52.215-22	Limitations on Pass-Through Charges—Identification of Subcontract Effort	OCT 2009   
	52.219-8	Utilization of Small Business Concerns	JAN 2011   
	52.219-9 Alt II	Small Business Subcontracting Plan (JAN 2011) Alternate II	OCT 2001   
	52.219-16	 Liquidated Damages-Subcontracting Plan	JAN 1999   
	52.222-3	Convict Labor	JUN 2003   
	52.222-21	Prohibition Of Segregated Facilities	FEB 1999   
	52.222-26	Equal Opportunity	MAR 2007   
	52.222-35	Equal Opportunity for Veterans	SEP 2010   
	52.222-36	Affirmative Action For Workers With Disabilities	OCT 2010   
	52.222-37	Employment Reports on Veterans	SEP 2010   
	52.222-38	Compliance With Veterans' Employment Reporting Requirements	SEP 2010   
	52.222-50	Combating Trafficking in Persons	FEB 2009   
	52.222-54	Employment Eligibility Verification	JUL 2012   
	52.223-6	Drug-Free Workplace	MAY 2001   
	52.223-18	Encouraging Contractor Policies To Ban Text Messaging While Driving	AUG 2011   
	52.225-13	Restrictions on Certain Foreign Purchases	JUN 2008   
	52.227-1	Authorization and Consent	DEC 2007   
	52.227-11	Patent Rights—Ownership By The Contractor	DEC 2007   
	52.227-14	Rights in Data—General	DEC 2007   
	52.227-16	Additional Data Requirements	JUN 1987   
	52.229-3	Federal, State And Local Taxes	APR 2003   
	52.232-2	Payments Under Fixed-Price Research And Development Contracts	APR 1984   
	52.232-23	Assignment Of Claims	JAN 1986   
	52.232-25	Prompt Payment	OCT 2008

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 17 of 32

    

 

	52.232-33	Payment by Electronic Funds Transfer—Central Contractor Registration	OCT 2003   
	52.233-1	Disputes	JUL 2002   
	52.233-3	Protest After Award	AUG 1996   
	52.233-4	Applicable Law for Breach of Contract Claim	OCT 2004   
	52.242-13	Bankruptcy	JUL 1995   
	52.243-7	Notification Of Changes	APR 1984   
	52.246-23	Limitation Of Liability	FEB 1997   
	52.246-25	Limitation Of Liability—Services	FEB 1997   
	52.249-2	Termination For Convenience Of The Government (Fixed-Price)	APR 2012   
	52.249-9	Default (Fixed-Priced Research And Development)	APR 1984   
	252.227-7013	Rights in Technical Data—Noncommercial Items	FEB 2012   
	252.227-7016	Rights in Bid or Proposal Information	JAN 2011   
	252.227-7017	Identification and Assertion of Use, Release, or Disclosure Restrictions	JAN 2011   
	252.227-7025	Limitations on the Use or Disclosure of Government-Furnished Information Marked with Restrictive Legends	MAR 2011   
	252.227-7037	Validation of Restrictive Markings on Technical Data	JUN 2012   
	252.227-7039	Patents—Reporting Of Subject Inventions	APR 1990   
	252.235-7011	Final Scientific or Technical Report	NOV 2004   

 

CLAUSES INCORPORATED BY FULL TEXT

 

52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT (MAR 2000)

 

(a) The Government may extend the term of this contract by written
notice to the Contractor within 30 days provided that the Government gives the Contractor a preliminary written notice of its intent
to extend at least 60 days,before the contract expires. The preliminary notice does not commit the Government to an extension.

 

(b) If the Government exercises this option, the extended contract
shall be considered to include this option clause.

 

(c) The total duration of this contract, including the exercise
of any options under this clause, shall not exceed five years.

(End of clause)

 

52.219-28 POST-AWARD SMALL BUSINESS PROGRAM REREPRESENTATION
(APR 2012)

 

(a) Definitions. As used in this clause—

 

Long-term contract means a contract of more than five years
in duration, including options. However, the term does not include contracts that exceed five years in duration because the period
of performance has been extended for a cumulative period not to exceed six months under the clause at 52.217-8, Option to Extend
Services, or other appropriate authority.

 

Small business concern means a concern, including its affiliates,
that is independently owned and operated, not dominant in the field of operation in which it is bidding on Government contracts,
and qualified as a small business under the criteria in 13 CFR part 121 and the size standard in paragraph (c) of this clause.
Such a concern is ``not dominant in its field of operation'' when it does not exercise a controlling or major influence on a national
basis in a kind of business activity in which a number of business concerns are primarily engaged. In determining whether dominance
exists, consideration shall be given to all appropriate factors, including volume of business, number of employees, financial resources,
competitive status or position, ownership or control of materials, processes, patents, license agreements, facilities, sales territory,
and nature of business activity.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 18 of 32

    

 

(b) If the Contractor represented that it was a small business
concern prior to award of this contract, the Contractor shall rerepresent its size status according to paragraph (e) of this clause
or, if applicable, paragraph (g) of this clause, upon the occurrence of any of the following:

 

(1) Within 30 days after execution of a novation agreement or
within 30 days after modification of the contract to include this clause, if the novation agreement was executed prior to inclusion
of this clause in the contract.

 

(2) Within 30 days after a merger or acquisition that does not
require a novation or within 30 days after modification of the contract to include this clause, if the merger or acquisition occurred
prior to inclusion of this clause in the contract.

 

(3) For long-term contracts—

 

(i) Within 60 to 120 days prior to the end of the fifth year
of the contract; and

 

(ii) Within 60 to 120 days prior to the date specified in the
contract for exercising any option thereafter.

 

(c) The Contractor shall rerepresent its size status in accordance
with the size standard in effect at the time of this rerepresentation that corresponds to the North American Industry Classification
System (NAICS) code assigned to this contract. The small business size standard corresponding to this NAICS code can be found at
http://www.sba.gov/content/table-small-business-size-standards.

 

(d) The small business size standard for a Contractor providing
a product which it does not manufacture itself, for a contract other than a construction or service contract, is 500 employees.

 

(e) Except as provided in paragraph (g) of this clause, the
Contractor shall make the rerepresentation required by paragraph (b) of this clause by validating or updating all its representations
in the Online Representations and Certifications Application and its data in the Central Contractor Registration, as necessary,
to ensure that they reflect the Contractor's current status. The Contractor shall notify the contracting office in writing within
the timeframes specified in paragraph (b) of this clause that the data have been validated or updated, and provide the date of
the validation or update.

 

(f) If the Contractor represented that it was other than a small
business concern prior to award of this contract, the Contractor may, but is not required to, take the actions required by paragraphs
(e) or (g) of this clause.

 

(g) If the Contractor does not have representations and certifications
in ORCA, or does not have a representation in ORCA for the NAICS code applicable to this contract, the Contractor is required to
complete the following rerepresentation and submit it to the contracting office, along with the contract number and the date on
which the rerepresentation was completed:

 

The Contractor represents that it ( ) is, ( ) is not a small
business concern under NAICS Code 541712- assigned to contract number N62645-12-C-4079.

 

(Contractor to sign and date and insert authorized signer's
name and title).

 

(End of clause)

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 19 of 32

    

 

52.243-1 CHANGES—FIXED-PRICE (AUG 1987)

 

(a) The Contracting Officer may at any time, by written order,
and without notice to the sureties, if any, make changes within the general scope of this contract in any one or more of the following:

 

(1) Drawings, designs, or specifications when the supplies to
be furnished are to be specially manufactured for the Government in accordance with the drawings, designs, or specifications.

 

(2) Method of shipment or packing.

 

(3) Place of delivery.

 

(b) If any such change causes an increase or decrease in the
cost of, or the time required for, performance of any part of the work under this contract, whether or not changed by the order,
the Contracting Officer shall make an equitable adjustment in the contract price, the delivery schedule, or both, and shall modify
the contract.

 

(c) The Contractor must assert its right to an adjustment under
this clause within 30 days from the date of receipt of the written order. However, if the Contracting Officer decides that
the facts justify it, the Contracting Officer may receive and act upon a proposal submitted before final payment of the contract.

 

(d) If the Contractor’s proposal includes the cost of
property made obsolete or excess by the change, the Contracting Officer shall have the right to prescribe the manner of the disposition
of the property.

 

(e) Failure to agree to any adjustment shall be a dispute under
the Disputes clause. However, nothing in this clause shall excuse the Contractor from proceeding with the contract as changed.

 

(End of clause)

 

52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)

 

This contract incorporates one or more clauses by reference,
with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text
available. Also, the full text of a clause may be accessed electronically at this/these address(es):

 

http://farsite.hill.af.mil/

 

(End of clause)

 

252.235-7010 Acknowledgment of Support and Disclaimer. (MAY
1995)

 

(a) The
Contractor shall include an acknowledgment of the Government's support in the publication of any material based on or developed
under this contract, stated in the following terms: This material is based upon work supported by the Naval Medical Logistics Command
under Contract No. N62645-12-C-4079.

 

(b) All material, except scientific articles or papers published
in scientific journals, must, in addition to any notices or disclaimers by the Contractor, also contain the following disclaimer:
Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily
reflect the views of the the Naval Medical Logistics Command.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 20 of 32

    

 

Section J - List of Documents, Exhibits and Other Attachments

 

CONTRACT ADMINISTRATION PLAN

CONTRACT ADMINISTRATION PLAN (CAP)

R&D Projects

 

1. Definitions.

 

1.1 Alternate Contracting Officer’s Representative (ACOR).
In the absence of the Contracting Officer’s Representative (COR), the Government official appointed in writing by the Contracting
Officer who functions as the technical representative of the Contracting Officer for a specific contract, for a specified period
of time.

 

1.2 Bureau of Medicine and Surgery (BUMED). The Department of
the Navy command responsible for all Navy medicine healthcare and research initiatives.

 

1.3 Commanding Officer. The senior Officer that has ultimate
responsibility for the operation of the research activity.

 

1.4 Contracting Officer. The Government official at the Naval
Medical Logistics Command with the actual authority to enter into, administer, and/or terminate contracts and make related determinations
and findings on the behalf of the Government.

 

1.5 Contracting Officer’s Representative (COR). The Government
official appointed in writing by the Contracting Officer who functions as the technical representative of the Contracting Officer
under the contract.

 

1.6 Contractor. The organization identified as the contractor/offeror
on the Standard Form 1449 and its employees who are performing research under the contract. The contractor is responsible for overall
performance under the contract even though its Principal Investigator has a significant responsibility for the research work.

 

1.7 Military Treatment Facility (MTF). A Department of Defense
(DoD) hospital or medical or health center where research may be required to be performed under this contract. The abbreviation,
“MTF” includes all Branch Medical or Health Clinics, Medical Administrative Units, Branch Medical or Health Annexes
and other subordinate clinical activities.

 

1.8 Naval Medical Logistics Command (NMLC). The Department of
the Navy command responsible for providing contract support for BUMED.

 

1.9 Principal Investigator (PI). The contractor employee responsible
for managing a research effort or project from a scientific or technical standpoint. The PI is responsible for the conduct of the
research work.

 

1.10 Research Activity. The Government center, laboratory, or
organization responsible for carrying out the research initiatives of BUMED.

 

1.11 Technical Assistant (TA). The research activity representative
who may be assigned by the COR to provide technical or administrative assistance to the COR. TAs may be assigned to assist and
support the COR but shall not be given the authority to provide any technical direction or clarification directly to the Contractor.

 

2. Responsibilities.

 

2.1 The Contracting Officer, Acquisition Management Directorate
(Code 02), Naval Medical Logistics Command shall:

 

2.1.1 Perform all required pre-award actions including providing
information or answering questions that arise during the solicitation period and as a result of Freedom of Information Act (FOIA)
inquiries.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	 

    	Page 21 of 32

    

  

2.1.2 Review the Contract Administration Plan (CAP). The Contracting
Officer shall furnish sample COR and TA nomination letters to the research activity in accordance with NAVSUPINST 4205.3 (series).

 

2.1.3 Verify that the individual(s) nominated to act as COR
and/or ACOR have had the required training and the necessary experience. If the Contracting Officer determines that a nominee does
not meet experience and training requirements, the Contracting Officer shall request that the research activity nominate another
individual.

 

2.1.4 Review the CAP prior to incorporation into the solicitation.
This review shall ensure that all contract administration functions are assigned, suit the specific circumstances of the contract
and give due consideration to the type of contract, the place of performance, period of performance, and inspection and acceptance
criteria stated in the solicitation/contract.

 

2.1.5 Include the COR duties contained in this CAP in the resultant
solicitation/contract. Additional duties shall be separately delineated within the contract, as appropriate.

 

2.1.6 Designate the paying office in the contract.

 

2.1.7 Appoint the COR and ACOR.

 

2.1.8 Perform all contract administration duties of a Contracting
Officer. Regular meetings between the Contracting Officer, the COR or the research activity Commanding Officer (or representative)
will be held to discuss the status of and the performance under individual contracts. The format and frequency of these meetings
will depend upon the size and complexity of the contract.

 

NOTE: All parties are specifically reminded that only the Contracting
Officer has the authority to modify the terms of the contract. Therefore, in no event will any understanding, agreement, modification,
change order, or other matter deviating from the terms of the contract between the Contractor and any other person be effective
or binding on the Government. When/if, in the opinion of the Contractor, any direction affecting the terms of the contract has
been given by the COR or any other person, the Contractor shall promptly notify the Contracting Officer.

 

2.1.9 Evaluate reports of Contractor non-compliance and take
appropriate action within 30 days of receipt. Copies of any correspondence regarding the results of such analyses shall be provided
to the research activity and the COR simultaneously with the action taken.

 

2.1.10 Arrange the post-award conference, if required. Invite
necessary attendees. Ensure that the requirements of the contract and the COR’s duties are thoroughly discussed and understood.
Ensure that all personnel involved understand current DoD Standards of Conduct policies.

 

2.1.11 Oversee the performance of CORs under the contract. Prompt
action shall be taken when COR (or alternate) is not performing properly.

 

2.1.12 Maintain the official contract file including modifications
(and all back-up documentation).

 

2.1.13 Maintain the accuracy of this CAP throughout the life
of the contract.

 

2.1.14 Maintain a list of all CORs under their authority. Periodically
review the files and performance of these CORs in accordance with NAVSUPINST 4205.3 (series) and local policies.

 

2.1.15 Review the existing annual Contractor performance report
prior to extending the contract or exercising any options under the contract.

 

2.2. The Commanding Officer of The Research Activity (or designated
representative) shall:

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 22 of 32

    

 

2.2.1 Establish research policy guidance.

 

2.2.2 Provide overall direction for research sponsored by the
activity.

 

2.2.3 Budget and provide funding for the contract.

 

2.2.4 Nominate (to the Contracting Officer) an individual to
be appointed as COR (by name, title, organizational code and telephone number). This individual shall also be the contract quality
assurance monitor and lead technical advisor to the Contracting Officer and shall be responsible for the technical interface needed
during contract performance. An ACOR can be nominated to act in the absence of the COR, when needed, or to provide additional expertise.
The COR nomination should be approved through the Department of Defense Contracting Office Representative Tracking (CORT) Tool
at: https://arc.army.mil/DoDCOR/

 

NOTE: COR duties cannot be delegated. The COR shall be accountable
for the actions of ACORs.

 

NOTE: Nomination of new CORs as a result of reassignment, termination
of employment, etc., shall be made in accordance with the procedures outlined herein.

 

2.2.5 Ensure all individuals nominated as COR or ACOR have the
necessary qualifications to satisfactorily perform the required duties and hold a position of responsibility commensurate with
the complexity of the contract. All CORs must complete DAU CLC 106. In addition CORs should complete a Naval Supply System Command
(NAVSUP) or BUMED approved COR training course (or DAU/ DoD equivalents) prior to appointment under complex contracts.

 

2.2.6 Support and supervise the COR in the performance of his/her
duties. If the Commanding Officer determines that assigned duties are not being performed in a satisfactory manner, immediate corrective
action shall be taken (including the recommendation to replace the COR if required). The Contracting Officer shall be promptly
notified of all actions taken. The research activity should consider COR performance in rating all individuals assigned COR functions.

 

2.2.7 Ensure that appropriate timely action is taken on all
contract related correspondence received from either the Contracting Officer or COR. This includes the timely submission (to the
Contracting Officer) of any requests for changes to the contract, deviations or waivers. An Independent Government Cost Estimate
of the impact on contract price and the availability of additional funding (if required) must accompany all requests for changes
to the contract. The Contractor’s price quote and the rationale for requesting the change shall accompany any changes proposed
by the Contractor. The Contractor’s price quote serves as a budgetary estimate of the cost impact. The research activity
shall also provide input as to technical acceptability of proposed contract language changes.

 

2.2.8 The research activity Commanding Officer may appoint a
TA to assist the COR in executing routine contract administration, monitoring and, surveillance duties. The appointment of all
TAs must be in writing and must include the TA's responsibilities and limitations. A copy of this appointment letter shall be provided
to the Contracting Officer. Before appointment, the research activity shall assure that all TAs have the appropriate training and
experience. TAs must complete DAU CLC 106 prior to appointment.

 

2.3 The Contracting Officer's Representative (COR) shall:

 

2.3.1 Notify the Contracting Officer in writing of any organizational
or personnel changes affecting the CAP.

 

2.3.2 Attend both the pre-proposal and post-award conferences,
if held.

 

2.3.3 Upon receipt of the contract from the Contracting Officer,
forward copies of documents to staff having administrative responsibilities for the contract.

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 23 of 32

    

 

2.3.4 Attend periodic meetings (as necessary) among the Contracting
Officer, research activity and Contractor to discuss the status of and performance under the contract.

 

2.3.5 Avoid issuing any instructions that would constitute a
change to the contract. The COR and Contractor shall not enter into any understanding, agreement, modification, or change order
deviating from the terms of the contract which shall be effective or binding on the Government. If in the opinion of the Contractor,
an effort outside the scope of the contract is requested, the Contractor shall promptly notify the Contracting Officer in writing.
The Contractor shall not act unless the Contracting Officer has issued a written change to the contract. The COR will include,
on all correspondence to the Contractor, a declination of authority statement as follows:

 

“I have neither the authority nor the intent to change
the terms or conditions of this contract. This contract can only be changed by a written modification issued by the Contracting
Officer. If you believe that I am requesting an effort outside the scope of this contract, promptly notify the Contracting Officer.
Additionally, this shall not be construed as an authorization for new work or additional work not already contained in the contract.”

 

2.3.6 Perform as the technical interface between the Government
and the Contractor for this contract. The COR shall provide technical advice or clarification regarding the statement of work and
terms of the contract; milestones to be met within the general terms of the contract or specific subtasks of the contract. The
COR is the point of contact through whom the Contractor can relay technical questions and problems to the Contracting Officer.
The Contractor may also contact the Contracting Officer directly.

 

2.3.7 Coordinate/facilitate complete and timely approvals for
any work at Government facilities between the research activity and the Contractor.

 

2.3.8 Ensure that the contractor has received and maintains
any required human subject or animal use research approvals. The COR shall coordinate any required reviews or actions with the
cognizant Human Research Protection Official (HRPO) or Animal Use Administrator (AUA).

 

2.3.9 Monitor Contractor performance and progress under the
contract. If potentially inefficient or wasteful methods are being used, the COR shall take reasonable and timely action to alert
the Contractor and the Contracting Officer. Furthermore, the COR shall promptly advise the Contracting Officer of any observed
continuous and/or substantial deficiencies in the Contractor's performance or other noncompliance with the terms and conditions
of the contract.

 

2.3.10 In accordance with procedures given in this CAP, promptly
issue Contract Discrepancy Reports (CDRs) (Enclosure (1)) to the Contractor to document discrepant performance. The COR shall always
obtain the Contractor's response/rebuttal to the CDR, evaluate the acceptability of the response and promptly forward the CDR,
Contractor response/rebuttal, and their recommendation to the Contracting Officer.

 

2.3.11 The COR shall recognize that CDRs become official records
within the contract file and that they have serious implications for overall contract management and relationships. CDRs shall
not be the first and only choice for communicating contract issues with the contractor and shall be implemented in accordance with
the procedures given below within this CAP.

 

2.3.12 For serious contract performance deficiencies, or when
less formal communications fail to resolve minor performance deficiencies, the COR will issue a CDR to the Contractor.

 

2.3.13 The COR shall ensure that all inspection data is attached
to the CDR. The Contractor cannot be expected to respond to performance deficiencies that are not clearly and specifically identified.
A cover memorandum on the CDR should specify that the Contractor has three working days, or other appropriate deadline, to respond
in writing to the COR. At the time the CDR is issued to the Contractor, the COR shall provide a copy of the CDR to the Contracting
Officer.

 

2.3.14 Upon return of the CDR package from the Contractor, the
COR shall review the Contractor’s comments and give careful, objective consideration to the facts and mitigating circumstances
documented in the response. The COR shall then make a final written determination and recommendation to the Contracting Officer
on the acceptability of Contractor performance and note it on the CDR. The COR shall state why the Contractor’s response
does or does not have merit. The COR shall prepare the determination, recommendation, and other statements as appropriate along
with actions being requested of the Contracting Officer and as much additional documentation as required to support their conclusions
and recommendations.

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 24 of 32

    

 

2.3.15 The COR shall provide the above documentation along with
actions being requested of the Contracting Officer and as much additional documentation as required to support their conclusions
and recommendations to (1) the Contractor, and (2) the Contracting Officer.

 

2.3.16 The Contracting Officer will review CDRs and will advise
the COR of the need for any further documentation.

 

2.3.17 Monitor and verify that research is provided in accordance
with the statement of work and terms of the contract. Keep accurate records of Contractor performance and compare these records
with the Wide Area Work Flow (WAWF) invoice submitted by the Contractor. The COR shall always use this information as a tool when
evaluating Contractor invoices. Monthly Progress Reports should be compared with their corresponding contractor invoices to verify
consistency between the two. The COR should review the acceptability of invoices by consideration of the following:

 

(a) Is the project on schedule?

(b) Are there any performance issues?

(c) Are costs appropriate considering current
progress of project?

(d) Are technical reports (quarterly, annual,
final) up to date?

(e) Are any required human subject or animal
use approvals in place?

 

2.3.18 Notify the Contracting Officer of questioned costs or
issues. As required, assist the Contracting Officer in resolving questioned costs or issues with the contractor.

 

2.3.19 Accept research deliverables as the official Government
representative.

 

2.3.20 Use appropriate methods for contract surveillance.

 

2.3.21 Understand contract invoicing requirements. The COR shall
ensure that all WAWF Invoices are processed in a timely manner so that prompt payment due dates are met. Prior to acceptance of
a WAWF invoice, the processing official shall obtain approval from the COR that the payment request is appropriate. This can be
done by having the COR sign a DD250 (or provide an e-mail to the contractor) for uploading into WAWF with the invoice. When the
WAWF invoice comes up in the WAWF system, the processing official can then see that approval has already been given by the COR.

 

2.3.22 Immediately alert the Contracting Officer of any unusual
performance problems. If a corrective action plan is approved by the Contracting Officer, the COR shall monitor the implementation
and effectiveness of that corrective action plan. In uncertain situations, the COR shall always seek advice from the Contracting
Officer, as prudent, before acting.

 

2.3.23 Perform administrative duties including maintaining files
which support the actions performed as a COR. The COR shall respond to all contract correspondence in a timely manner. Contract
files shall include a conforming copy of the contract, all modifications, a conforming copy of the Contractor’s Technical
Proposal, all surveillance reports, each CDR (including the Contractor’s response/rebuttal), any contract-related correspondence,
a contract log or COR diary, all telephone conversation and email records, meeting minutes, reports from Government subject matter
experts, and Independent Government Cost Estimates.

 

2.3.24 If applicable, take the necessary steps to ensure that
Government property furnished to the Contractor is provided in a timely manner and in proper condition for use. The COR shall maintain
both inventory and disposition records for all Government furnished property. This inventory/disposition file is coordinated with
the Contracting Officer. The COR shall ensure that the Contractor returns all Government furnished property or that Government
furnished material has been reasonably consumed in the performance of work.

 

2.3.25 Read and comply with all applicable Standards of Conduct
and Conflict of Interest instructions and procedures including annual financial interest filings.

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 25 of 32

    

 

2.3.26 Ensure that the Contractor receives copies of all regulations
and/or directives considered appropriate to the research being performed.

 

2.3.27 Submit information detailing the Contractor's performance
to the Contracting Officer. A statement indicating performance has been satisfactory along with your request to continue performance
would be required prior to extending the contract or exercising options under the contract. An annual report on the Contractor's
performance will be required 30 days after the end of each performance period. A final report shall be sent to the Contracting
Officer within 60 days after completion of the contract. The final report shall contain a conclusive statement describing the Contractor's
overall performance and an evaluation on the accountability of Government property furnished to the Contractor. An addendum report
may also be required. Format for the report will be in consonance with the Contractor Performance Assessment Reporting System (CPARS)
and is provided at Enclosure (2).

 

2.3.28 Perform other duties, particular to the contract, as
may be incorporated into the contract document or as required by the Contracting Officer.

 

2.3.29 Generate monthly COR reports and quarterly surveillance
reports to the Contracting Officer and COR file.

 

2.3.30 The COR should self nominate himself/herself through
the Department of Defense Contracting Office Representative Tracking (CORT) Tool at: https://arc.army.mil/DoDCOR/. The CORT
Tool should also be utilized to assist in the performance of the COR responsibilities.

 

2.4 Technical Assistant (TA). All requirements for TA duties
are reported directly to the COR. At the direction of the COR, the TA shall:

 

2.4.1 Perform surveillance and identify Contractor deficiencies.

 

2.4.2 Review contract deliverables, recommending acceptance/rejection,
and providing the COR with the documentation to support all recommendations.

 

2.4.3 Assist the COR in the preparation of the final Contractor
performance report using the format and procedures prescribed by the Contracting Officer.

 

2.4.4 Identify Contractor non-compliance with reporting requirements.

 

2.4.5 Evaluate Contractor proposals, identifying potential problem
areas.

 

2.4.6 Provide to the COR (a) recommendations for revisions or
clarifications to the statement of work and terms of the contract and (b) recommendations for revisions to the CAP.

 

2.4.7 Provide detailed written reports of any trip, meeting,
correspondence, telephone conversation, email or anecdotal conversation after any contact between the TA and the Contractor.

 

Enclosures:

Enclosure 1 - Contract Discrepancy Report

Enclosure 2 – Contractor Performance Assessment Report

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions
have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 26 of 32

    

 

Enclosure 1 - Contract Discrepancy Report

 

	CONTRACT DISCREPANCY REPORT
	
        Contract Number:

         

         
	Contract Clause:	Date:
	
        COR Findings:

         

         

         

         

         

         

         

         

         

	
        COR (sign and date):

         

         

	
        Contractor Response:

         

         

         

         

         

         

         

         

	
        Contractor Project Manager (sign and date):

         

         

	
        COR Determination/Recommendation:

         

         

         

         

         

         

         

         

         

         

         

	
        COR (sign and date):

         

         

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 27 of 32

    

 

Enclosure 2 – Contractor Performance Assessment Report

	
         

        CONTRACTOR PERFORMANCE ASSESSMENT REPORT

         

 

Contractor Name and Address:

 

	Company Name:

 

	Street Address:

 

	Report Type: {Annual or Final or Addendum}

 

	Period of Performance Being Assessed:

 

	Contract Number:

 

	Order Number:

 

	Location of Contract Performance:

 

	
        Program Title:

         

         

 

	
        Contract Effort Description:

         

         

         

 

Key Subcontractor(s):

 

	
        Contractor Name:

        Effort Performed:

         

 

	
        Contractor Name:

        Effort Performed:

         

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 28 of 32

    

 

	Evaluation Ratings Definitions (Excluding Utilization of Small Business)

	 	 	 	 	 
	Rating	 	Definition	 	Note
	 	 	 	 	 
	Exceptional	 	Performance meets contractual requirements and exceeds many to the Government’s benefit. The contractual performance of the element or sub-element being assessed was accomplished with few minor problems for which corrective actions taken by the contractor was highly effective.

	 	To justify an Exceptional rating, identify multiple significant events and state how they were of benefit to the Government. A singular benefit, however, could be of such magnitude that it alone constitutes an Exceptional rating. Also, there should have been NO significant weaknesses identified.
	 	 	 	 	 
	Very Good	 	Performance meets contractual requirements and exceeds some to the Government’s benefit. The contractual performance of the element or sub-element being assessed was accomplished with some minor problems for which corrective actions taken by the contractor was effective.	 	To justify a Very Good rating, identify a significant event and state how it was a benefit to the Government. There should have been no significant weaknesses identified.
	 	 	 	 	 
	Satisfactory	 	Performance meets contractual requirements. The contractual performance of the element or sub-element contains some minor problems for which corrective actions taken by the contractor appear or were satisfactory.	 	To justify a Satisfactory rating, there should have been only minor problems, or major problems the contractor recovered from without impact to the contract. There should have been NO significant weaknesses identified. A fundamental principle of assigning ratings is that contractors will not be assessed a rating lower than Satisfactory solely for not performing beyond the requirements of the contract.
	 	 	 	 	 
	Marginal	 	Performance does not meet some contractual requirements. The contractual performance of the element or sub-element being assessed reflects a serious problem for which the contractor has not yet identified corrective actions. The contractor’s proposed actions appear only marginally effective or were not fully implemented.	 	To justify Marginal performance, identify a significant event in each category that the contractor had trouble overcoming and state how it impacted the Government. A Marginal rating should be supported by referencing the management tool that notified the contractor of the contractual deficiency (e.g., management, quality, safety, or environmental deficiency report or letter).
	 	 	 	 	 
	Unsatisfactory	 	Performance does not meet most contractual requirements and recovery is not likely in a timely manner. The contractual performance of the element or sub-element contains a serious problem(s) for which the contractor’s corrective actions appear or were ineffective.	 	To justify an Unsatisfactory rating, identify multiple significant events in each category that the contractor had trouble overcoming and state how it impacted the Government. A singular problem, however, could be of such serious magnitude that it alone constitutes an unsatisfactory rating. An Unsatisfactory rating should be supported by referencing the management tools used to notify the contractor of the contractual deficiencies (e.g., management, quality, safety, or environmental deficiency reports, or letters).

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 29 of 32

    

 

	Evaluation Ratings Definitions (Utilization of Small Business)
	 
	Rating	 	Definition	 	Note
	 	 	 	 	 
	Exceptional	 	Exceeded all negotiated subcontracting goals or exceeded at least one goal and met all of the other negotiated subcontracting goals for the current period. Had exceptional success with initiatives to assist, promote, and utilize small business (SB), small disadvantaged business (SDB), women-owned small business (WOSB), HUBZone small business, veteran-owned small business (VOSB) and service disabled veteran owned small business (SDVOSB). Complied with FAR 52.219-8, Utilization of Small Business Concerns. Exceeded any other small business participation requirements incorporated in the contract, including the use of small businesses in mission critical aspects of the program. Went above and beyond the required elements of the subcontracting plan and other small business requirements of the contract. Completed and submitted Individual Subcontract Reports and/or Summary Subcontract Reports in an accurate and timely manner.	 	To justify an Exceptional rating, identify multiple significant events and state how they were a benefit to small business utilization. A singular benefit, however, could be of such magnitude that it constitutes an Exceptional rating. Ensure that small businesses are given meaningful, innovative work directly related to the project, rather than peripheral work, such as cleaning offices, supplies, landscaping, etc. Also, there should have been no significant weaknesses identified.
	 	 	 	 	 
	Very Good	 	Met all of the negotiated subcontracting goals in the traditional socio-economic categories (SB, SDB and WOSB) and met at least one of the other socio-economic goals (HUBZone, VOSB, SDVOSB) for the current period. Had significant success with initiatives to assist, promote and utilize SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB. Complied with FAR 52.219-8, Utilization of Small Business Concerns. Met or exceeded any other small business participation requirements incorporated in the contract, including the use of small businesses in mission critical aspects of the program. Endeavored to go above and beyond the required elements of the subcontracting plan. Completed and submitted Individual Subcontract Reports and/or Summary Subcontract Reports in an accurate and timely manner.	 	To justify a Very Good rating, identify a significant event and state how they were a benefit to small business utilization. Ensure that small businesses are given meaningful, innovative work directly related to the project, rather than peripheral work, such as cleaning offices, supplies, landscaping, etc. There should be no significant weaknesses identified.

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 30 of 32

    

 

	Satisfactory	 	Demonstrated a good faith effort to meet all of the negotiated subcontracting goals in the various socio-economic categories for the current period. Complied with FAR 52.219-8, Utilization of Small Business Concerns. Met any other small business participation requirements included in the contract. Fulfilled the requirements of the subcontracting plan included in the contract. Completed and submitted Individual Subcontract Reports and/or Summary Subcontract Reports in an accurate and timely manner.	 	To justify a Satisfactory rating, there should have been only minor problems, or major problems the contractor has addressed or taken corrective action. There should have been no significant weaknesses identified. A fundamental principle of assigning ratings is that contractors will not be assessed a rating lower than Satisfactory solely for not performing beyond the requirements of the contract.
	 	 	 	 	 
	Marginal	 	Deficient in meeting key subcontracting plan elements. Deficient in complying with FAR 52.219-8, Utilization of Small Business Concerns, and any other small business participation requirements in the contract. Did not submit Individual Subcontract Reports and/or Summary Subcontract Reports in an accurate or timely manner. Failed to satisfy one or more requirements of a corrective action plan currently in place; however, does show an interest in bringing performance to a satisfactory level and has demonstrated a commitment to apply the necessary resources to do so. Required a corrective action plan.	 	To justify Marginal performance, identify a significant event that the contractor had trouble overcoming and how it impacted small business utilization. A Marginal rating should be supported by referencing the actions taken by the government that notified the contractor of the contractual deficiency.
	 	 	 	 	 
	Unsatisfactory	 	Noncompliant with FAR 52.219-8 and 52.219-9, and any other small business participation requirements in the contract. Did not submit Individual Subcontract Reports and/or Summary Subcontract Reports in an accurate or timely manner. Showed little interest in bringing performance to a satisfactory level or is generally uncooperative. Required a corrective action plan.	 	To justify an Unsatisfactory rating, identify multiple significant events that the contractor had trouble overcoming and state how it impacted small business utilization. A singular problem, however, could be of such serious magnitude that it alone constitutes an Unsatisfactory rating. An Unsatisfactory rating should be supported by referencing the actions taken by the government to notify the contractor of the deficiencies. When an Unsatisfactory rating is justified, the contracting officer must consider whether the contractor made a good faith effort to comply with the requirements of the subcontracting plan required by FAR 52.219-9 and follow the procedures outlined in FAR 52.219-16, Liquidated Damages-Subcontracting Plan.

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 31 of 32

    

 

NOTE 1: Generally, zero percent is not a goal unless the Contracting
Officer determined when negotiating the subcontracting plan that no subcontracting opportunities exist in a particular socio-economic
category. In such cases, the contractor shall be considered to have met the goal for any socio-economic category where the goal
negotiated in the plan was zero.

 

Assigned Rating

 

	Evaluation Area	 	Prior Rating	 	Current Rating
	
         

        Quality of Product or Service

         
	 	 	 	 
	
        Schedule

         
	 	 	 	 
	
         

        Cost Control

         

        (Not required for Firm-Fixed Price or Firm-Fixed Price with
        Economic Price Adjustment)

         
	 	 	 	 
	
        Business Relations

         
	 	 	 	 
	
         

        Management of Key Personnel

         

        (For Services and Information Technology Business Sectors only
        - Not Applicable to Operations Support)

         
	 	 	 	 
	
         

        Utilization of Small Business

         
	 	Assessed by Contracting Officer	 	Assessed by Contracting Officer
	
        Other Areas:

         
	 	 	 	 
	
        (1) {list}

         
	 	 	 	 
	
        (2) {list}

         
	 	 	 	 
	(3) {list}	 	 	 	 

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	Page 32 of 32

    

 

Rating Support

 

Note: A factual narrative is required for all assessments
regardless of rating. Each narrative statement in support of the area assessment must contain objective data.

 

	
        Quality of Product or Service Narrative:

         

         

         

	
        Schedule Narrative:

         

         

         

	
        Cost Control Narrative (if applicable):

         

         

         

	
        Business Relations Narrative:

         

         

         

	
        Management of Key Personnel Narrative (if applicable):

         

         

         

	
        Other Areas (1) Narrative:

         

         

         

	
        Other Areas (2) Narrative:

         

         

         

	
        Other Areas (3) Narrative:

         

         

         

 

	COR Name:	 
	
         

        Signature:

         
	 
	Date:	 

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	 

    

 

 

 

Attachment 1: Statement of Work

 

Manufacture
of Three Adenovirus Vectors Encoding Plasmodium falciparum Sporozoite/Liver Stage Antigens with Stability Program

 

Prepared for:

 

Naval Medical Research Center

 

Submitted by:

 

GenVec, Inc.

 

65 West Watkins Mill Road

 

Gaithersburg, MD 20878

 

Date:

 

28-September-2012

 

	 	Business Contact:	Technical Contact:
	 	Cynthia L. Collins	Bryan T. Butman, Ph.D.
	 	President and CEO	Senior VP, Development
	 	240-632-5500	240-632-5554
	 	ccollins@genvec.com	bbutman@genvec.com

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	 

    	 

    

 

Table of Contents

 

	1.	Executive Summary	3
	2.	Background	4
	3.	Scope of Work	5
	4.	List of Subcontractors	15
	5.	Supporting Capabilities	16
	6.	Key Personnel	17
	7.	Summary	19
	8.	Appendices	20
	 	Appendix A: Overview of Manufacturing Process for CSS and MVB/CTM BDS Lots	21
	 	Appendix B: Overall Testing Plan for Adenovector Malaria Vaccines	22
	 	Appendix C: Testing Performed for Certification of Vector Seed Stocks (VSS)	23
	 	Appendix D: Testing Plan for Release of GMP Clinical Seed Stocks (CSS)	24
	 	Appendix E: Testing Plan for Release of GMP MVB/CTM Bulk Drug Substance (BDS)	25
	 	Appendix F: Testing Plan for Release of GMP Vaccine Final Drug Product (FDP)	26
	 	Appendix G:  Stability Testing Plan for Vaccine Final Drug Product (FDP)	27
	 	Appendix H: Detailed Project Time Line	28

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	2

    	 

    

 

1.
Executive Summary

 

GenVec proposes to establish vector seed stocks and then conduct
cGMP manufacture and testing of three separately vialed adenoviral vectored malaria vaccine vectors to be used in Phase 1 clinical
trial(s) by the Naval Medical Research Center (NMRC). These vectors will encode Plasmodium falciparum genes for *.

 

The proposed scope of work is as follows:

		·	Task #1: Construction, Production (non-GMP) and Characterization of three (3) Vector Seed Stocks (VSS) (CLIN 0001)

		·	Task #2: Manufacture (GMP) and testing of three (3) Clinical Seed Stocks (CSS) (CLIN 0002)

		·	Task #3A: Manufacture (GMP) and testing of three (3) Master Virus Bank/Clinical Trial Material (MVB/CTM) Bulk Drug Substance
lots (CLIN 0002)

		·	Task #3B: Manufacture (GMP) and testing of three (3) vaccine Final Drug Product (FDP) lots (CLIN 0002 and CLIN
2001)

		·	Task #4: Stability study on these three (3) vialed vaccine FDP lots according to ICH guidelines (for a period of 36
months) (CLIN 0003 and CLIN 1001)

		·	Task #5: Storage and shipment of products manufactured under proposal (CLIN 0002)

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	3

    	 

    

 

2.
Background

 

One of the missions of NMRC is to develop
a malaria vaccine. GenVec is a small biotech company focusing on advancing our adenovector-based gene delivery platform to develop
novel vaccines and therapeutics. GenVec has previously collaborated with NMRC on development and clinical testing of two first
generation adenovirus serotype 5 (Ad5) -based adenovector vaccines. We showed that a DNA prime - Ad5 boost regimen expressing CSP
and AMA1 antigens protected 4/15 volunteers from experimental challenge. Three out of four of the protected individuals had the
most robust AMA1-specific T cell responses. These data support the growing body of evidence indicating that prime-boost regimens
that include an adenovector component can provide protection against malaria.

 

The
threshold for licensure of military malaria vaccine is * efficacy. Our current goal is to improve an adenovector-based vaccine
and obtain * protection in the human experimental challenge model. We have a two-pronged, rational approach to build and
test a malaria vaccine product that can meet this objective by incorporating highly protective malaria antigens into GenVec’s
improved vaccine delivery vectors (GCXX).

 

The next developmental step is to combine three antigens from the
Plasmodium falciparum parasite, that have previously shown evidence for inducing protection in the human Phase 1 clinical
testing, into an improved adenovector vaccine. This vaccine will be tested * for protection using the human experimental challenge
model. The three malaria antigens of interest under this program are:

		·	*

		·	*

		·	*

 

*

 

GenVec has developed a novel vector-based gene delivery technology
(adenovirus “GCXX” backbone) that is uniquely suited for malaria vaccine development. GenVec’s GCXX vectors are
highly immunogenic in mice and provided protection in the mouse malaria, P. yoelii, challenge model. In addition, these
vectors are derived from adenovirus serotypes that do not infect humans and were shown by GenVec to have very low seroprevalence
in the US population. Furthermore, GenVec has extensive experience in cGMP manufacture and testing, as well as regulatory experience
with FDA, to enable moving adenoviral vectored vaccines into clinical testing.

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	4

    	 

    

 

3.
Scope of Work

 

Objectives: The overall objective is to generate three
cGMP-compliant clinical trial material (CTM) lots for use in Phase 1 trial(s) by NMRC (using the three pre-GMP VSS lots prepared
under Task #1, below). This will require successive generation (two-tiered GMP plan) of a GMP Clinical Seed Stock (CSS) bulk drug
lot (GMP Tier 1), followed by production of a GMP Master Virus Bank (MVB)/Clinical Trial Material (CTM) bulk drug substance lot
(GMP Tier 2), with GMP vialing of Final Drug Product (FDP), for each of these three malaria vaccine vectors. GenVec will use best
efforts to achieve the objectives in the Scope of Work. The overall production scheme is outlined below:

 

 

* The asterisk denotes
that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934.
The confidential portions have been submitted separately to the Securities and Exchange Commission.

 

    	5

    	 

    

 

Overview of GenVec Manufacturing Approach: GenVec
has manufactured more than * lots of clinical trial materials for both vaccine and therapeutic products. GenVec's approach has
met the cGMP requirements of the FDA for numerous Phase 1 and Phase 2 vaccine clinical trials for both Malaria and HIV vaccines.

 

GenVec proposes to use our proprietary 293 ORF6 cell line, which
provides  appropriate complementation of the deleted adenoviral E1 and E4 sequences, to enable efficient production of these
replication-deficient GCXX vectors. GenVec has extensively characterized the 293 ORF6 Master Cell Bank (MCB) and has submitted
a Master File to FDA, which can be cross-referenced by NMRC in the IND submission. This Master File contains all of the details
regarding production and testing of the Master and Working cell banks for 293 ORF6.

 

In order to manufacture the CSS and MVB/CTM lots, GenVec will
use the production process outlined in Appendix A. The basic manufacturing process will involve: Expansion of GenVec's proprietary
293 ORF6 production cell line in serum-free suspension culture —> virus infection/production —> harvest/recovery
—> purification * —> formulation, final filtration and filling.

 

All products made under this contract will be produced using
animal-free materials. Extensive Quality Control release testing will be performed on the CSS, MVB/CTM and FDP lots. The overall
QC testing plan for each step in the production plan is defined in Appendix B. The Vector Seed Stocks to be used as viral
seeds for the GMP production will be certified by GenVec Quality Assurance according to the plan defined in Appendix C.

 

Quality Assurance: GenVec will establish a Quality Agreement
with NMRC outlining the level of quality and NMRC/GenVec responsibilities prior to *

  

Project Management: GenVec will assign a Project Manager
to assure that all activities are conducted according to the established scope of work and program time line. In order to facilitate
communications between GenVec and NMRC, regular teleconferences will be held. The frequency of these teleconferences will be dependent
upon the needs of the program. The Agenda and Minutes for these teleconferences will be generated by the GenVec Project Manager.

 

Regulatory Support of NMRC IND: GenVec will provide *.
GenVec will also*.

GenVec proposes to provide our expertise to provide the following
services:

 

* The asterisk denotes that confidential
portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential
portions have been submitted separately to the Securities and Exchange Commission.

 

    	6

    	 

    

 

Task #1: Generation of three GCXX-Pf Vector Seed Stocks
(VSS) – GenVec proposes to manufacture three VSS lots within our Gaithersburg, MD research laboratories using GenVec's
proprietary 293-ORF6 cells. The specific GCXX backbone will be chosen based on the performance of various backbones, tested under
CRADA (NMR-12-4076). Each VSS will consist of the chosen GCXX backbone expressing *. The three VSS will be produced using GenVec’s
standard VSS production process, which is comparable to that used to manufacture the MVB/CTM lots. VSS will be manufactured at
an appropriate scale to produce * or greater particle units (PU) of each GCXX-Pf VSS lot. Each VSS lot will be vialed into standard
* and stored frozen at *. GenVec Research will coordinate testing of the three VSS lots as defined in Appendix C. *

 

*

 

Deliverables for Task #1: Vector Seed Stock Lots

		1.	*

		2.	*

 

* The
asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange
Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	7

    	 

    

 

Task #2: Clinical Seed Stocks - GenVec proposes
to conduct GMP manufacture of the three CSS lots *, using the production process outlined in Appendix A, in a manner that
is comparable to the MVB/CTM bulk drug substance lots. Clinical Seed Stock release testing is defined in Appendix D. GenVec
Quality Control will coordinate testing of the three CSS lots. *.

 

*

 

At the end of NMRC's GLP toxicology study, GenVec will provide
the following analytical support:

		·	*.

		·	*.

 

The CSS lots will also be used as the GMP viral lots that will
seed the production of the three MVB/CTM bulk drug substance lots. GenVec Quality Assurance will conduct review and release of
the three CSS lots.

 

GenVec will provide Technical Summary Reports for each of the
three GCXX Pf CSS lots.

 

Reference Standard vials from each of the three CSS lots will
be filled into cryovials for use in MVB/CTM and FDP QC Release and Stability assays for transgene expression. Following lot release,
Reference Standard vials for future stability time points will be provided to NMRC.

 

Deliverables for Task #2: Clinical Seed Stock Lots

		·	CSS vials to support immunology and toxicology preclinical studies from each of three malaria vaccine vectors, stored at *. The
target will be * PU of each vector for delivery to NMRC.

 

		·	Reference Standard vials for use in future stability time points (after release of FDP).

 

		·	*

 

		·	*

 

		·	*

 

		·	*

 

		·	*

 

		·	*

 

		·	*

 

* The
asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange
Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	8

    	 

    

 

Task #3A: MVB/CTM Bulk Drug Substance - A
single BDS lot will be manufactured for each of the three malaria constructs, using the three CSS lots described above. *.
For GMP manufacture of the three MVB/CTM BDS lots, GenVec will use the production process outlined in Appendix A.
Release testing for the MVB/CTM BDS is defined in Appendix E.

 

*

 

*

 

The proposed manufacturing and testing plans will be reviewed
by the FDA. Modifications to these may be required per FDA pre-IND meeting feedback, and will be accommodated if not burdensome.

 

*

 

The comprehensive MVB/CTM bulk drug substance release testing
plan is defined in Appendix E. This includes both cell harvest and final BDS testing for safety, potency, purity and identity.
Testing will be coordinated by GenVec Quality Control. GenVec Quality Assurance will conduct review and release of the three MVB/CTM
BDS lots.

 

Deliverables for Task #3A: MVB/CTM Bulk Drug Substance
Lots

 

		·	*

 

		·	*

 

		·	*

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	9

    	 

    

 

Task #3B: Vaccine Final Drug Product (FDP) - Each
of the three CTM bulk drug substance lots will be formulated with Final Formulation Buffer (FFB) and vialed separately as three
Final Drug Product (FDP) lots at an appropriate vector concentration and volume, per the needs of the NMRC Phase 1 clinical trial(s).
The filling process and containers will first be qualified to assure aseptic filling of the FDP. The target concentration for each
FDP lot will be *. *

 

It is understood that NMRC desires approximately * vials per
lot (including CTM, QC release, stability and retain vials). The Vaccine Final Drug Product testing for safety, potency, integrity
and purity is defined in Appendix F. GenVec Quality Control will coordinate this testing.

 

For filling of the three FDP vaccine lots, *. A sufficient number
of vials for each lot will be filled * and frozen at *. As stated above, any remaining MVB/CTM BDS will be stored frozen * in *.
GenVec Quality Assurance will conduct review and release of the three FDP lots. A sufficient number of FDP vials will be put aside
from each lot to enable a * stability study. As described below, a 36 month stability study is within the scope of this proposal
(Task #4). After GenVec QA release of the three FDP lots, GenVec will ship these materials to NMRC for long-term storage. NMRC
shall be notified by GenVec of any retained lots and of all intended and actual uses of these retained lots and afford NMRC right
to approve such uses, which shall not be unreasonably withheld.

 

GenVec will also provide Vialed Final Formulation Buffer (FFB)
for NMRC use as a diluent/placebo in Phase 1 clinical studies. Up to 100 vials of GMP-released FFB will be provided, with a target
fill volume of *. These FFB vials will be covered under an existing stability program. GenVec will provide a copy of a relevant
stability report for this FFB lot.

 

Deliverables for Task # 3B: Vaccine Final Drug Product
Lots

 

		·	Shipment of all FDP vials (less retain samples), including stability vials from each of the three malaria vaccine vectors,
stored at *. *

 

		·	True and exact copies of executed batch production and testing records for three FDP lots.

 

		·	Vialed Final Formulation Buffer (FFB) for NMRC use as a diluent/placebo in Phase 1 clinical studies from. Up to 100 vials of
GMP-released FFB will be provided, with a target fill volume of *.

 

		·	Certificates of Analysis (certified by GenVec Quality Control and Quality Assurance, reviewed and approved by NMRC) containing
the test results for the *three Vaccine FDP lots; marked to reflect NMRC Proprietary information.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	10

    	 

    

 

		·	GenVec Certificate of Analysis and relevant stability report for the already vialed FFB/Diluent lot.

 

		·	Product liability insurance for the FDP lots to be used in clinical trials, for a period of * years upon the Government’s
exercise and funding of Option CLIN 2001.

 

		·	Provide an MSDS for the GCXX Pf manufactured products if requested by NMRC/NMRC representatives.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	11

    	 

    

 

Task #4: 36-Month ICH Stability Program for Three FDP
Lots

 

Objective: The objective of Task 4 is to conduct a 36
month stability study in accordance with ICH guidelines in order to monitor potency and integrity of the vaccine FDP lots during
the Phase 1 clinical trials. A sufficient number of FDP vials will be set aside to accommodate a *stability study. GenVec stability
testing beyond the * month time frame will require exercise of Option CLIN 1001.

 

At the beginning of the stability protocol, vialed FDP from
each of the three vectors will be shipped to NMRC, who will be responsible for storage of stability vials in temperature-controlled
chambers at *. Upon request with suitable advance notice, NMRC will ship vials to GenVec for testing according to the stability
testing plan outlined in Appendix G. The individual time points in the stability protocol will be * months. Only time points
* months are addressed under CLIN 0003. The remaining time points (* months are addressed under Option CLIN 1001, below.

The stability study will be designed to synchronize each time
point for all * FDP lots. Accordingly, the study will not be initiated until all three lots of FDP have been filled. The T=0 data
will come from the lot release testing for the three FDP lots.

 

At the beginning of the stability study, GenVec will establish
QA approved stability protocols, for each of the three lots that define the list of tests (per the above plan), specifications
and frequency of testing. GenVec will store the samples under controlled conditions (at a contract repository) and will conduct
testing under this plan according to established QC SOPs.

 

Deliverables for Task #4

		·	Subsequent
                                                                                                               to each testing
                                                                                                               time point, GenVec
                                                                                                               Quality Control
                                                                                                               will prepare a
                                                                                                               Stability Time
                                                                                                               Point Report of
                                                                                                               the data. The GenVec
                                                                                                               Quality Assurance-approved
                                                                                                               reports will be
                                                                                                               provided to NMRC
                                                                                                               within 60 days
                                                                                                               of the stability
                                                                                                               time point.

		·	*

		·	At the end
                                                                                                               of the proposed
                                                                                                               * month stability
                                                                                                               study under CLIN
                                                                                                               0003, GenVec will
                                                                                                               provide a Summary
                                                                                                               Report for each
                                                                                                               of the three vaccine
                                                                                                               vector FDP lots;
                                                                                                               marked to reflect
                                                                                                               NMRC Propriety
                                                                                                               information.

 

*
The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission
..

 

    	12

    	 

    

 

 

Task #5: Storage and Shipment - GenVec will store
all produced materials at either * or *. GenVec will be responsible for controlled monitoring and inventory of these materials
until shipments are made to NMRC.

 

Shipment of vials from the three CSS lots is addressed under
Task #2, above.

 

Shipment of the vials for use in the Phase 1 clinical trial
is addressed under Task #3B, above.

 

Shipment of the vials for use in the 36 month stability program
is addressed under Task #4, above.

 

NMRC will be responsible to take possession and to
arrange for long-term storage and inventory of all contract materials shipped by GenVec. All materials will be packaged for shipment
to ensure maintenance of proper temperature and product integrity. In order to mitigate risk, GenVec will split each lot into two
shipments). This shipment to the NMRC designated storage facility will be coordinated with an appropriate NMRC representative.
All vector products and samples will be protected from exposure to carbon dioxide from dry ice during shipment *

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	13

    	 

    

 

Period of Performance and Timing for Tasks 1-5:

 

The project start date will be determined by NMRC.
The following is an approximate project schedule. GenVec will use best efforts to accomplish the objectives consistent with this
schedule.

 

Period of Performance #1: * months

		·	Task #1: Construction, Production and Characterization of 3 VSS Lots - * months.

		a.	Generation of VSS Reports – *wks.

		·	Task #2: GMP Manufacture, Testing and Release of 3 CSS lots - * months (overlaps VSS construction and manufacture).

		a.	Generation of CSS Technical Summary Reports - * month.

		·	Task #3A: GMP Manufacture, Testing and GenVec QA Release of 3 MVB/CTM BDS lots (includes technology transfer to CMO)
- * months.

		·	Task #3B: GMP Manufacture, Testing and GenVec QA Release of 3 Vaccine FDP lots – * months (includes qualification
of the filling process and overlaps BDS manufacture).

		·	Task #5: Storage - Duration of manufacturing campaign.

 

Period of Performance #2: * months (months *)

 

		·	Task #4: Stability Program - * months from release testing of 3rd FDP lot (T=0) – CLIN 0003.

 

Period of Performance #3: Twenty-four (24) months
(months *)

 

Task #4: Stability Program – Option
CLIN 1001.

 

The detailed project Time Line is presented in Appendix
H, with a start date of * for the purpose of generating the time line.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	14

    	 

    

 

		4.	List of Subcontractors

 

The following GenVec QA vendor qualified*subcontractors are
proposed to be used during the performance of this contract: 

 

	Name	 	Location	 	Service Provided
	*	 	*	 	Contract GMP Manufacturing
	*	 	*	 	Safety Testing Services
	*	 	*	 	Safety Testing Services
	*	 	*	 	Impurity Testing Services
	*	 	*	 	Microbiological Testing Services
	*	 	*	 	DNA Sequencing Services
	*	 	*	 	GMP Storage Services

 

*Vendor qualification reports are available to NMRC for review
upon NMRC’s request.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	15

    	 

    

 

		5.	Supporting Capabilities

 

Documentation 

GenVec has developed a Document Management Program that applies
to the management of all controlled documents including those associated with cGMP. This serves as a tracking tool for GenVec documents,
including the *documents, and is able to scan and retrieve documents or images, index, sort, search, track versions and provide
lists and reports related to GenVec documentation.

 

Project Management

GenVec will assign a Project Manager from within its Development
department. It is the Project Manager’s responsibility to plan for activities directly and indirectly related to performance
of the project. This includes the assembly of a project team with adequate representation from the key disciplines to conduct the
work, development of a Gantt chart that details the activities and timing required to complete the defined work, and tracking information
to ensure that the project is being conducted within appropriate cost parameters. The Project Manager is responsible for supporting
the overall resources of the project and making certain communication flows in the most effective manner between collaborators.
The Project Manager is also responsible for ensuring that reporting complies with the contract.

 

In order to facilitate communications between GenVec and NMRC,
regular teleconferences will be held. The frequency of these teleconferences will be dependent upon the needs of the program. The
Agenda and Minutes for these teleconferences will be generated by the GenVec Project Manager.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	16

    	 

    

 

		6.	Key Personnel

 

Bryan Butman, Ph.D., Senior Vice President, Development

Role and Responsibility: Dr. Butman will be responsible
for allocating resources and managing the overall performance of the GMP manufacturing and testing program. Manufacturing Science,
Quality Control, Quality Assurance, Regulatory Affairs and Project Management all report into him. Dr. Butman has over 27 years
of biotechnology product development experience, including 13 years experience in Process Development, Manufacturing, Quality Control
and Quality Assurance at GenVec. He also has extensive experience communicating with FDA CBER on clinical development of adenoviral
vectors.

 

Joe Bruder, Ph.D., Director, Research &Head of Malaria

Role and Responsibility: Dr. Bruder is GenVec's Head
of the Malaria Vaccine Program. His primary responsibility is to lead GenVec’s research and development efforts in the development
of a highly protective malaria vaccine. Specifically, Dr. Bruder will be responsible for communication and coordination of research
and development activities with the NMRC. He will provide scientific oversight for the project, oversee vector construction, VSS
production and characterization and write a research report detailing the VSS production and testing. Dr. Bruder has worked in
the adenoviral research and product development for 19 years at GenVec. He has led GenVec's Malaria Vaccine Program for 9 years.

 

Perry Newton, Director, Manufacturing Sciences

Role and Responsibility: Mr. Newton will be responsible
for establishing the manufacturing process and for overseeing the production of the CSS, MVB/CTM and FDP lots. He has more than
18 years experience managing cGMP manufacture of CTM for adenoviral and retroviral constructs.

 

Clement J. Purcell, Director, Quality Control/Quality Assurance

Role and Responsibility: Mr. Purcell’s primary
responsibilities as they relate to this proposal are the direction of all Quality Control and Quality Assurance personnel and operations
involved with the project. Mr. Purcell has been employed in the biotechnology field for more than 25 years and in a Quality role
supporting both clinical and commercial manufacturing and technology transfer for more than 22 years.

 

Frances Cox, Manager, Document Control

Role and Responsibility: Ms. Cox’s primary responsibility
as it relates to this proposal is the control and maintenance of all manufacturing and testing documentation. She is responsible
for the coordination of routing documents and tracking the status of document review and approval. In addition to managing internal
distribution of controlled documents, it is her responsibility to transfer and track documentation shared with collaborators. Ms.
Cox has over 9 years experience at GenVec and over 30 years experience with project and executive office administration.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	17

    	 

    

 

Francesca Reed, Project Manager

Role and Responsibility: Ms. Reed’s primary responsibility
as it relates to this proposal is as the Project Manager for this project. Ms. Reed has over 14 years experience in the biotechnology
field and 5 years as a Project Manager.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	18

    	 

    

 

		7.	Summary

 

GenVec proposes to perform five tasks for the manufacture
of three adenovector malaria vaccine vectors using our proprietary biological materials and processes. The overall goal is to provide
cGMP Clinical Trial Materials (CTM) for use by NMRC in Phase 1 clinical trials of a trivalent adenovector vaccine for malaria.
GenVec will use best efforts to achieve the objectives in the Scope of Work.

 

		·	Under Task #1, GenVec will construct, manufacture (non-GMP) and characterize three Vector Seed Stocks (VSS) on the "GCXX"
backbone.

 

		·	Under Task #2, GenVec will be responsible for GMP manufacture, testing and release of Clinical Seed Stocks (CSS) for
each of these three malaria vaccine constructs. Under this task, GenVec will also provide bulk filled Final Formulation Buffer
(FFB).

 

		·	Under Task 3, GenVec will be responsible for GMP manufacture and testing of three MVB/CTM bulk drug substance lots (Task
#3A) and three corresponding vaccine Final Drug Product (FDP) lots (Task #3B) for use in Phase 1 clinical trials by NMRC. GenVec
will provide vialed FFB for clinical use. Under this task, GenVec will also provide CMC regulatory support to NMRC's IND filing
and will provide product liability insurance for a period of * during conduct of the Phase 1 trial upon the Government’s
exercise and funding of the Option CLIN 2001.

 

		·	Under Task 4, GenVec will conduct a stability program of three vaccine FDP lots for a period of 36 months, according
to ICH Guidelines (inclusive of CLIN 0003 and Option CLIN 1001 if exercised and funded by the Government).

 

		·	Under Task 5, GenVec will store, according to cGMP requirements, all contract products and samples until they are shipped
to an NMRC-designated repository.

 

Note: The proposed testing plans are subject to FDA feedback
and may require refinement or modifications accordingly. These modifications will be accommodated if not burdensome.

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	19

    	 

    

 

		8.	Appendices

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	20

    	 

    

 

Appendix A: Overview of Manufacturing
Process for CSS and MVB/CTM BDS Lots

 

*

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	21

    	 

    

 

 

Appendix B: Overall Testing Plan for
Adenovector Malaria Vaccines

*

		·	*

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	22

    	 

    

 

Appendix C: Testing Performed for Certification
of Vector Seed Stocks (VSS)

 

	Test	 	Performed By	 	Method
	*	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	23

    	 

    

 

Appendix D: Testing Plan for Release
of GMP Clinical Seed Stocks (CSS)

 

	Test	 	Laboratory	 	Protocol	 	Specification
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	24

    	 

    

 

Appendix E: Testing Plan for Release
of GMP MVB/CTM Bulk Drug Substance (BDS)

 

	Tests Performed on Unprocessed Cell Harvest
	Test	 	Laboratory	 	Protocol	 	Specification
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	Tests Performed on Purified Bulk
	Test	 	Laboratory	 	Protocol	 	Specification
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	 	 	 	 	 	 	 

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	25

    	 

    

Appendix F: Testing Plan for Release
of GMP Vaccine Final Drug Product (FDP)

 

	Test	 	Laboratory	 	Protocol	 	Specification
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*

 

Footnote for Appendix F:

 

*

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	26

    	 

    

 

Appendix G: Stability Testing Plan
for Vaccine Final Drug Product (FDP)

 

	
        Time Point (Month)

        Test
	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	*	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	*	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	*	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	*	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	*	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	*	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	*	 	 	 	 	 	 	 	*	 	 	 	*	 	 
	*	 	 	 	 	 	 	 	*	 	 	 	*	 	*
	*	 	 	 	 	 	 	 	 	 	 	 	 	 	*

  

Footnotes for Appendix G:

 

		·	*

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	27

    	 

    

 

Appendix H: Detailed Project Timeline

 

*

 

* The asterisk
denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of
1934. The confidential portions have been submitted separately to the Securities and Exchange Commission .

 

    	28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]